



北京健康(控股)有限公司

Beijing Health (Holdings) Limited

Incorporated in the Cayman Islands with limited liability
於開曼群島註冊成立之有限公司

Stock Code 股份代號 : 2389



2022

Interim Report
中期報告

CONTENTS

目錄

Unaudited Interim Financial Information
未經審核中期財務資料

Interim Condensed Consolidated:
中期簡明綜合：

- 2** Statement of Profit or Loss and Other Comprehensive Income
損益及其他全面收益表
- 5** Statement of Financial Position
財務狀況表
- 7** Statement of Changes in Equity
權益變動表
- 9** Statement of Cash Flows
現金流量表
- 12** Notes to Interim Condensed Consolidated Financial Information
中期簡明綜合財務資料附註
- 46** Management Discussion and Analysis
管理層討論及分析
- 66** Additional Information
額外資料
- 79** Corporate Information
公司資料



INTERIM RESULTS

The board of directors (the “Board”) of Beijing Health (Holdings) Limited (the “Company”) presents the unaudited interim condensed consolidated financial information of the Company and its subsidiaries (collectively the “Group”) for the six months ended 30 June 2022, together with the comparative figures for the corresponding period in 2021. The interim condensed consolidated financial information have not been audited, but have been reviewed by the Company’s audit committee.

中期業績

北京健康(控股)有限公司(「本公司」)董事會(「董事會」)提呈本公司及其附屬公司(統稱「本集團」)截至二零二二年六月三十日止六個月的未經審核中期簡明綜合財務資料，連同二零二一年同期的比較數字。中期簡明綜合財務資料未經審核，惟已由本公司審核委員會審閱。

INTERIM CONDENSED CONSOLIDATED STATEMENT OF PROFIT OR LOSS AND OTHER COMPREHENSIVE INCOME

中期簡明綜合損益及其他全面收益表

For the six months ended 30 June 2022 截至二零二二年六月三十日止六個月

			2022 二零二二年 HK\$'000 千港元 (Unaudited) (未經審核)	2021 二零二一年 HK\$'000 千港元 (Unaudited) (未經審核)
Revenue	收入	4	91,807	79,619
Cost of sales	銷售成本		(66,553)	(57,065)
Gross profit	毛利		25,254	22,554
Other income and gains, net	其他收入及收益淨額	5	22,851	41,456
Selling and distribution expenses	銷售及分銷開支		(6,429)	(5,691)
Administrative expenses	行政開支		(55,951)	(63,293)
Impairment losses on financial assets	金融資產減值虧損		(2,849)	(1,106)
Other expenses and losses	其他開支及虧損		(1,806)	(5,356)
Finance costs	融資成本	6	(602)	(949)
Share of profits and losses of:	應佔溢利及虧損：			
Joint ventures	合營公司		(6,788)	(1,689)
Associates	聯營公司		(9,353)	(3,961)
LOSS BEFORE TAX	除稅前虧損	7	(35,673)	(18,035)
Income tax credit	所得稅抵免	8	1,286	6,590
LOSS FOR THE PERIOD	期間虧損		(34,387)	(11,445)

INTERIM CONDENSED CONSOLIDATED STATEMENT OF PROFIT OR LOSS AND OTHER COMPREHENSIVE INCOME

中期簡明綜合損益及其他全面收益表

For the six months ended 30 June 2022 截至二零二二年六月三十日止六個月

	Notes 附註	2022 二零二二年 HK\$'000 千港元 (Unaudited) (未經審核)	2021 二零二一年 HK\$'000 千港元 (Unaudited) (未經審核)
LOSS FOR THE PERIOD	期間虧損	(34,387)	(11,445)
OTHER COMPREHENSIVE INCOME/ (LOSS)	其他全面收益/(虧損)		
Other comprehensive income/(loss) that may be reclassified to profit or loss in subsequent periods:	其後期間可能重新分類至損益之其他全面收益/(虧損)：		
Debt investment at fair value through other comprehensive income:	按公平值計入其他全面收益的債權投資：		
Changes in fair value	公平值變動	891	(1,009)
Reclassification adjustment for gains included in the consolidated statement of profit or loss – gain on redemption	計入綜合損益表之收益之重新分類調整 – 贖回的收益	(905)	-
Exchange differences:	匯兌差額：		
Exchange differences on translation of foreign operations	換算海外業務之匯兌差額	(75,802)	19,534
Reclassification adjustment for a foreign operation deconsolidated during the period	期內海外業務不再綜合入賬之重新分類調整	(48)	-
Share of other comprehensive income/(loss) of a joint venture	應佔一間合營公司之其他全面收益/(虧損)	125	(253)
Share of other comprehensive loss of an associate	應佔一間聯營公司之其他全面虧損	(849)	(382)
Net other comprehensive (loss)/income that may be reclassified to profit or loss in subsequent periods	其後期間可能重新分類至損益之其他全面(虧損)/收益淨額	(76,588)	17,890
Other comprehensive loss that will not to be reclassified to profit or loss in subsequent periods:	其後期間將不會重新分類至損益之其他全面虧損：		
Change in fair value of equity instruments designated at fair value through other comprehensive income	指定為透過其他全面收益以公平值列賬之權益工具之公平值變動	(16,929)	(24,054)
OTHER COMPREHENSIVE LOSS FOR THE PERIOD	期間其他全面虧損	(93,517)	(6,164)
TOTAL COMPREHENSIVE LOSS FOR THE PERIOD	期間全面虧損總額	(127,904)	(17,609)

INTERIM CONDENSED CONSOLIDATED STATEMENT OF PROFIT OR LOSS AND OTHER COMPREHENSIVE INCOME

中期簡明綜合損益及其他全面收益表

For the six months ended 30 June 2022 截至二零二二年六月三十日止六個月

	Note	2022 二零二二年 HK\$'000 千港元 (Unaudited) (未經審核)	2021 二零二一年 HK\$'000 千港元 (Unaudited) (未經審核)
	附註		
(Loss)/profit attributable to:	下列人士應佔(虧損)/溢利:		
Owners of the parent	母公司擁有人	(32,820)	(12,318)
Non-controlling interests	非控股權益	(1,567)	873
		(34,387)	(11,445)
Total comprehensive loss attributable to:	下列人士應佔全面虧損總額:		
Owners of the parent	母公司擁有人	(110,666)	(12,541)
Non-controlling interests	非控股權益	(17,238)	(5,068)
		(127,904)	(17,609)
LOSS PER SHARE ATTRIBUTABLE TO ORDINARY EQUITY HOLDERS OF THE PARENT	母公司普通股權益持有人應佔每股虧損		
	10		
Basic and diluted	基本及攤薄	HK(0.54) cents (0.54)港仙	HK(0.20) cents (0.20)港仙

INTERIM CONDENSED CONSOLIDATED STATEMENT OF FINANCIAL POSITION

中期簡明綜合財務狀況表

30 June 2022 二零二二年六月三十日

		Notes 附註	30 June 2022 二零二二年 六月三十日 HK\$'000 千港元 (Unaudited) (未經審核)	31 December 2021 二零二一年 十二月三十一日 HK\$'000 千港元 (Audited) (經審核)
NON-CURRENT ASSETS	非流動資產			
Property, plant and equipment	物業、廠房及設備	11	78,648	84,594
Investment properties	投資物業		145,580	138,317
Right-of-use assets	使用權資產		441,006	470,073
Property under development	發展中物業		446,735	467,279
Goodwill	商譽		79,979	79,979
Investments in joint ventures	於合營公司之投資		90,274	97,533
Investments in associates	於聯營公司之投資		191,536	183,623
Equity investments designated at fair value through other comprehensive income	指定為透過其他全面收益以公平值列賬之權益投資		234,192	323,881
Debt investment at fair value through other comprehensive income	按公平值計入其他全面收益的債權投資		-	40,331
Prepayments and other receivables	預付款項及其他應收款項		204,380	201,523
Total non-current assets	非流動資產總值		1,912,330	2,087,133
CURRENT ASSETS	流動資產			
Inventories	存貨		45,704	70,731
Trade and bills receivables	應收貿易賬款及應收票據	12	42,405	34,799
Prepayments, other receivables and other assets	預付款項、其他應收款項及其他資產		116,143	148,998
Financial assets at fair value through profit or loss	透過損益以公平值列賬之金融資產		340,759	253,169
Restricted bank balances	受限制銀行結餘		4,120	3,994
Cash and cash equivalents	現金及現金等值物		137,928	239,136
Total current assets	流動資產總值		687,059	750,827
CURRENT LIABILITIES	流動負債			
Trade payables	應付貿易賬款	13	38,383	46,424
Other payables and accruals	其他應付款項及應計費用		134,745	156,323
Interest-bearing bank borrowings	計息銀行借款		36,905	36,693
Lease liabilities	租賃負債		5,802	6,223
Tax payable	應付稅款		1,078	637
Total current liabilities	流動負債總額		216,913	246,300
NET CURRENT ASSETS	流動資產淨值		470,146	504,527
TOTAL ASSETS LESS CURRENT LIABILITIES	總資產減流動負債		2,382,476	2,591,660

INTERIM CONDENSED CONSOLIDATED STATEMENT OF FINANCIAL POSITION

中期簡明綜合財務狀況表

30 June 2022 二零二二年六月三十日

		30 June 2022 二零二二年 六月三十日 HK\$'000 千港元 (Unaudited) (未經審核)	31 December 2021 二零二一年 十二月三十一日 HK\$'000 千港元 (Audited) (經審核)
NON-CURRENT LIABILITIES	非流動負債		
Other payables	其他應付款項	3,490	3,652
Lease liabilities	租賃負債	4,811	5,452
Deferred tax liabilities	遞延稅項負債	78,732	85,937
Total non-current liabilities	非流動負債總額	87,033	95,041
NET ASSETS	資產淨值	2,295,443	2,496,619
EQUITY	權益		
Equity attributable to the owners of the parent	母公司擁有人應佔權益		
Share capital	股本	1,215,789	1,215,789
Treasury shares	庫存股份	(1,920)	-
Reserves	儲備	967,169	1,077,835
		2,181,038	2,293,624
Non-controlling interests	非控股權益	114,405	202,995
TOTAL EQUITY	總權益	2,295,443	2,496,619

INTERIM CONDENSED CONSOLIDATED STATEMENT OF CHANGES IN EQUITY

中期簡明綜合權益變動表

For the six months ended 30 June 2022 截至二零二二年六月三十日止六個月

	Attributable to owners of the parent 母公司擁有人應佔												
	Share capital	Treasury shares	Share premium account	Statutory surplus reserve	Share option reserve	Other reserves	Exchange fluctuation reserve	Fair value reserve of financial assets at fair value through other comprehensive income	Accumulated losses	Total	Non-controlling interests	Total equity	
	股本 HK\$'000 千港元 (Unaudited) (未經審核) (note 14) (附註14)	庫存股份 HK\$'000 千港元	股份溢價賬 HK\$'000 千港元 (Unaudited) (未經審核)	法定盈餘 撥備 HK\$'000 千港元 (Unaudited) (未經審核)	購股權儲備 HK\$'000 千港元 (Unaudited) (未經審核) (note 15) (附註15)	其他儲備 HK\$'000 千港元 (Unaudited) (未經審核)	匯兌波動 儲備 HK\$'000 千港元 (Unaudited) (未經審核)	透過其他全面 收益以公平 價值列賬之 資產之 HK\$'000 千港元 (Unaudited) (未經審核)	累計虧損 HK\$'000 千港元 (Unaudited) (未經審核)	總計 HK\$'000 千港元 (Unaudited) (未經審核)	非控股權益 HK\$'000 千港元 (Unaudited) (未經審核)	總權益 HK\$'000 千港元 (Unaudited) (未經審核)	
At 1 January 2022	於二零二二年一月一日	2,215,789	-	1,771,142	16,405	88,865	31,153	18,044	(5,698)	(842,075)	2,293,624	202,895	2,496,619
Loss for the period	期間虧損	-	-	-	-	-	-	-	-	(32,820)	(32,820)	(1,567)	(34,387)
Other comprehensive income/(loss) for the period:	期間其他全面收益/(虧損):	-	-	-	-	-	-	-	-	-	-	-	-
Change in fair value of a debt investment at fair value through other comprehensive income	透過其他全面收益以公平價值列賬之債權投資的公平價值變動	-	-	-	-	-	-	-	891	-	891	-	891
Reclassification adjustment for a debt investment at fair value through other comprehensive income for loss included in profit or loss	虧備計入權益之按公平價值計入其他全面收益的債權投資的重新分類調整	-	-	-	-	-	-	-	(905)	-	(905)	-	(905)
Exchange differences on translation of foreign operations	換算海外業務的匯兌差額	-	-	-	-	-	(67,161)	-	-	-	(67,161)	(8,641)	(75,802)
Reclassification adjustment for a foreign operation deconsolidated during the period	期內海外業務不再綜合入賬之重新分類調整	-	-	-	-	-	(48)	-	-	-	(48)	-	(48)
Share of other comprehensive loss of a joint venture	應佔一間合營公司之其他全面虧損	-	-	-	-	-	125	-	-	-	125	-	125
Share of other comprehensive loss of an associate	應佔一間聯營公司之其他全面虧損	-	-	-	-	(849)	-	-	-	-	(849)	-	(849)
Change in fair value of equity investments designated at fair value through other comprehensive income	指定為透過其他全面收益以公平價值列賬之權益投資的公平價值變動	-	-	-	-	-	-	(9,899)	-	(9,899)	(7,030)	(16,929)	
Total comprehensive loss or the period	期間全面虧損總額	-	-	-	-	(849)	(67,084)	(9,913)	(32,820)	(110,666)	(17,238)	(127,904)	
Shares repurchased	購回股份	-	(1,920)	-	-	-	-	-	-	(1,920)	-	(1,920)	
Dividend to a non-controlling shareholder	向非控股股東的股息	-	-	-	-	-	-	-	-	-	(196)	(196)	
Reclassification adjustment of equity investments designated at fair value through other comprehensive income	指定為透過其他全面收益以公平價值列賬之權益投資的重新分類調整	-	-	-	-	-	-	7,814	(7,814)	-	-	-	
Deconsolidation of a subsidiary (note 16)	一間附屬公司不再綜合入賬(附註16)	-	-	-	-	-	-	-	-	-	(71,156)	(71,156)	
At 30 June 2022 (unaudited)	於二零二二年六月三十日(未經審核)	2,215,789	(1,920)	1,771,142*	16,405*	88,865*	30,304*	(49,040)*	(7,798)*	(882,709)*	2,181,038	114,405	2,295,443

INTERIM CONDENSED CONSOLIDATED STATEMENT OF CHANGES IN EQUITY

中期簡明綜合權益變動表

For the six months ended 30 June 2022 截至二零二二年六月三十日止六個月

		Attributable to owners of the parent 母公司擁有人應佔										
		Share capital	Share premium account	Statutory surplus reserve	Share option reserve	Other reserves	Exchange fluctuation reserve	Fair value reserve of financial assets at fair value through other comprehensive income	Accumulated losses	Total	Non-controlling interests	Total equity
		股本	股份溢價賬	法定盈餘儲備	購股權儲備	其他儲備	匯兌波動儲備	透過其他全面收益以公平值列賬之金融資產之	累計虧損	總計	非控股權益	總權益
		HK\$'000	HK\$'000	HK\$'000	HK\$'000	HK\$'000	HK\$'000	HK\$'000	HK\$'000	HK\$'000	HK\$'000	HK\$'000
		(Unaudited)	(Unaudited)	(Unaudited)	(Unaudited)	(Unaudited)	(Unaudited)	(Unaudited)	(Unaudited)	(Unaudited)	(Unaudited)	(Unaudited)
		(note 14)	(未經審核)	(未經審核)	(未經審核)	(未經審核)	(未經審核)	(未經審核)	(未經審核)	(未經審核)	(未經審核)	(未經審核)
		(附註14)			(附註15)							
At 1 January 2021	於二零二一年一月一日	1,215,789	1,771,142	16,405	98,514	23,422	(24,789)	(6,331)	(812,314)	2,281,838	209,202	2,491,040
Loss for the period	期間虧損	-	-	-	-	-	-	-	(12,318)	(12,318)	873	(11,445)
Other comprehensive income/(loss) for the period	期間其他全面收益/(虧損)	-	-	-	-	-	-	(1,009)	-	(1,009)	-	(1,009)
Change in fair value of a debt investment at fair value through other comprehensive income	透過其他全面收益以公平值列賬之債權投資之公平值變動	-	-	-	-	-	-	(1,009)	-	(1,009)	-	(1,009)
Exchange differences on translation of foreign operations	換算海外業務之匯兌差額	-	-	-	-	-	17,073	-	-	17,073	2,461	19,534
Share of other comprehensive loss of a joint venture	應佔一間合營公司之其他全面虧損	-	-	-	-	-	(253)	-	-	(253)	-	(253)
Share of other comprehensive loss of an associate	應佔一間聯營公司之其他全面虧損	-	-	-	-	(382)	-	-	-	(382)	-	(382)
Change in fair value of equity investments designated at fair value through other comprehensive income	指定為透過其他全面收益以公平值列賬之權益投資之公平值變動	-	-	-	-	-	-	(15,652)	-	(15,652)	(8,402)	(24,054)
Total comprehensive loss or the period	期間全面虧損總額	-	-	-	-	(382)	16,820	(16,661)	(12,318)	(12,541)	(5,068)	(17,609)
Share of reserve of an associate	分佔一間聯營公司之儲備	-	-	-	-	1,195	-	-	-	1,195	-	1,195
Transfer of share option reserve upon the cancellation of share options	購股權被註銷時轉撥購股權儲備	-	-	-	(9,649)	-	-	-	9,649	-	-	-
At 30 June 2021 (unaudited)	於二零二一年六月三十日(未經審核)	1,215,789	1,771,142*	16,405*	88,865*	24,235*	(7,969)*	(22,992)*	(814,983)*	2,270,492	204,134	2,474,626

* These reserve accounts comprise the consolidated reserves of HK\$967,169,000 (31 December 2021: HK\$1,077,835,000) in the condensed consolidated statement of financial position as at 30 June 2022.

* 於二零二二年六月三十日，該等儲備賬包括簡明綜合財務狀況表之綜合儲備967,169,000港元(二零二一年十二月三十一日：1,077,835,000港元)。

INTERIM CONDENSED CONSOLIDATED STATEMENT OF CASH FLOWS

中期簡明綜合現金流量表

For the six months ended 30 June 2022 截至二零二二年六月三十日止六個月

	Notes 附註	2022 二零二二年 HK\$'000 千港元 (Unaudited) (未經審核)	2021 二零二一年 HK\$'000 千港元 (Unaudited) (未經審核)
CASH FLOWS FROM OPERATING ACTIVITIES 經營活動所得現金流量			
Loss before tax: 除稅前虧損:		(35,673)	(18,035)
Adjustments for: 就以下各項作出調整:			
Finance costs 融資成本	6	602	949
Share of losses of joint ventures and associates 應佔合營企業及聯營公司之虧損		16,141	5,650
Bank interest income 銀行利息收入	5	(444)	(2,469)
Other interest and investment income 其他利息及投資收入	5	(10,752)	(14,237)
Depreciation of property, plant and equipment 物業、廠房及設備折舊	7	3,168	5,610
Depreciation of right-of-use assets 使用權資產折舊	7	10,974	11,768
Gain on disposal of property, plant and equipment 出售物業、廠房及設備的收益	11	(67)	-
Fair value losses on investment properties, net 投資物業公平值虧損淨額	5	2,656	959
Reversal of impairment loss on investment in an associate 撥回於一間聯營公司之投資的減值虧損	5	-	(13,527)
Impairment of financial assets 金融資產減值	7	2,849	1,106
Fair value losses on financial assets at fair value through profit or loss, net 透過損益以公平值列賬之金融資產之公平值虧損淨額	5	566	3,022
Gain on deconsolidation of a subsidiary 一間附屬公司不再綜合入賬的收益	7	(63)	-
Gain on disposal of an associate 出售一間聯營公司的收益	5	(858)	-
Gain on redemption of debt investment at fair value through other comprehensive income 贖回透過其他全面收益以公平值列賬之債權投資之收益		(4,375)	-
Gain on disposal of equity investment designated at fair value through other comprehensive income 出售指定為透過其他全面收益以公平值列賬之權益投資之收益		(1,410)	-
Loss on deemed partial disposal of an associate 被視為部分出售聯營公司的虧損	7	-	5,291
Dividend income 股息收入	5	(1,114)	(1,246)
		(17,800)	(15,159)
Decrease/(increase) in inventories 存貨減少/(增加)		23,141	(2,216)
Increase in trade receivables 應收貿易賬款增加		(11,755)	(817)
Decrease in prepayments, other receivables and other assets 預付款項、其他應收款項及其他資產減少		30,282	2,899
Decrease in trade payables 應付貿易賬款減少		(6,647)	(11,496)
Decrease in other payables and accruals 其他應付款項及應計費用減少		(18,511)	(16,110)
Increase in restricted bank balance 受限制銀行結餘增加		(126)	(7,362)
Effect of foreign exchange rate changes, net 匯率變動影響淨額		2,222	(9,747)
Cash generated from/(used in) in operations 經營所得/(所用)現金		806	(60,008)
PRC corporate income tax (paid)/refund, net 中國企業所得稅(支付)/退回淨額		(1,815)	4,380
Net cash flows used in operating activities 經營活動所用現金流量淨額		(1,009)	(55,628)

INTERIM CONDENSED CONSOLIDATED STATEMENT OF CASH FLOWS

中期簡明綜合現金流量表

For the six months ended 30 June 2022 截至二零二二年六月三十日止六個月

	2022 二零二二年 HK\$'000 千港元 (Unaudited) (未經審核)	2021 二零二一年 HK\$'000 千港元 (Unaudited) (未經審核)
CASH FLOWS FROM INVESTING ACTIVITIES	投資活動所得現金流量	
Bank interest income received	444	2,469
Other interest and investment income received	6,623	8,554
Purchase of property, plant and equipment	(904)	(2,250)
Purchase of an investment property	(15,914)	-
Proceeds from disposal of property, plant and equipment	104	19
Proceeds from disposal of a subsidiary	(14)	-
Proceeds from disposal of an associate	1,533	-
Additional investment in an associate	-	(1,189)
Purchase of equity investments at fair value through profit or loss	(228,178)	(13,454)
Proceeds from disposal of equity investments at fair value through profit or loss	126,047	11,511
Proceeds from disposal of equity investments designated at fair value through other comprehensive income	2,095	-
Purchases of a debt investment at fair value through other comprehensive income	(35,154)	-
Purchases of financial assets at fair value through other comprehensive income	(7,219)	-
Redemption of debt investments at fair value through other comprehensive income	78,194	-
Dividends received from listed equity investments	1,114	1,246
Deconsolidation of a subsidiary	(19,335)	-
Net cash flows (used in)/from investing activities	(90,564)	6,906

INTERIM CONDENSED CONSOLIDATED STATEMENT OF CASH FLOWS

中期簡明綜合現金流量表

For the six months ended 30 June 2022 截至二零二二年六月三十日止六個月

		2022 二零二二年 HK\$'000 千港元 (Unaudited) (未經審核)	2021 二零二一年 HK\$'000 千港元 (Unaudited) (未經審核)
CASH FLOWS FROM FINANCING ACTIVITIES	融資活動所得現金流量		
Interest paid	已付利息	(263)	(645)
New bank loans	新銀行貸款	37,807	49,112
Repayment of bank loans	償還銀行貸款	(36,255)	(43,116)
Principal portion of lease payments	租賃付款本金部分	(3,242)	(3,077)
Purchase of shares for cancellation	購買股份作註銷	(1,920)	-
Dividends paid to non-controlling shareholders	已付非控股股東之股息	(196)	-
		(4,069)	2,274
NET DECREASE IN CASH AND CASH EQUIVALENTS	現金及現金等值物減少淨額	(95,642)	(46,448)
Cash and cash equivalents at beginning of the period	期初現金及現金等值物	239,136	477,420
Effect of foreign exchange rate changes, net	匯率變動影響淨額	(5,566)	5,259
CASH AND CASH EQUIVALENTS AT END OF THE PERIOD	期末現金及現金等值物	137,928	436,231
ANALYSIS OF BALANCES OF CASH AND CASH EQUIVALENTS	現金及現金等值物結餘分析		
Cash and bank balances	現金及銀行結餘	94,308	433,360
Time deposits	定期存款	43,620	2,871
Cash and cash equivalents as stated in the condensed consolidated statement of cash flows	簡明綜合現金流量表所示之現金及現金等值物	137,928	436,231

NOTES TO INTERIM CONDENSED CONSOLIDATED FINANCIAL INFORMATION

中期簡明綜合財務資料附註

For the six months ended 30 June 2022 截至二零二二年六月三十日止六個月

1. CORPORATE INFORMATION

Beijing Health (Holdings) Limited (the “Company”) is a limited liability company incorporated in the Cayman Islands and its shares have been listed on the Main Board of The Stock Exchange of Hong Kong Limited (the “Stock Exchange”) since 26 April 2002. The registered office of the Company is located at Cricket Square, Hutchins Drive, P.O. Box 2681, KY1-1111, Grand Cayman, Cayman Islands.

During the period, the Company and its subsidiaries (collectively referred to as the “Group”) were involved in the provision of medical care, health care and geriatric care related services and products in the People’s Republic of China (the “PRC”).

2. BASIS OF PREPARATION AND ACCOUNTING POLICIES

2.1. BASIS OF PREPARATION

The interim condensed consolidated financial information for the six months ended 30 June 2022 has been prepared in accordance with the applicable disclosure requirements of Appendix 16 to The Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited (the “Listing Rules”) and Hong Kong Accounting Standard 34 *Interim Financial Reporting* issued by the Hong Kong Institute of Certified Public Accountants (“HKICPA”). The interim condensed consolidated financial information does not include all the information and disclosures required in the annual financial statements, and should be read in conjunction with the Group’s annual consolidated financial statements for the year ended 31 December 2021.

1. 公司資料

北京健康(控股)有限公司(「本公司」)為於開曼群島註冊成立之有限公司，其股份自二零二二年四月二十六日起在香港聯合交易所有限公司(「聯交所」)主板上市。本公司之註冊辦事處位於 Cricket Square, Hutchins Drive, P.O. Box 2681, KY1-1111, Grand Cayman, Cayman Islands。

期內，本公司及其附屬公司(統稱「本集團」)於中華人民共和國(「中國」)提供醫療、健康及養老相關服務及產品。

2. 編製基準及會計政策

2.1. 編製基準

截至二零二二年六月三十日止六個月之中期簡明綜合財務資料乃根據香港聯合交易所有限公司證券上市規則(「上市規則」)附錄16及香港會計師公會(「香港會計師公會」)頒佈的香港會計準則第34號*中期財務報告*的適用披露規定編製。中期簡明綜合財務資料並不包括年度財務報表所需一切資料及披露，並應與本集團截至二零二一年十二月三十一日止年度的年度綜合財務報表一併閱讀。

NOTES TO INTERIM CONDENSED CONSOLIDATED FINANCIAL INFORMATION

中期簡明綜合財務資料附註

For the six months ended 30 June 2022 截至二零二二年六月三十日止六個月

2. BASIS OF PREPARATION AND ACCOUNTING POLICIES – continued 2. 編製基準及會計政策—續

2.2. CHANGES IN ACCOUNTING POLICIES AND DISCLOSURES

The accounting policies adopted in the preparation of the interim condensed consolidated financial information are consistent with those applied in the preparation of the Group's annual consolidated financial statements for the year ended 31 December 2021, except for the adoption of the following revised Hong Kong Financial Reporting Standards ("HKFRSs") for the first time for the current period's financial information.

2.2. 會計政策及披露變動

編製中期簡明綜合財務資料所採納的會計政策與編製本集團截至二零二一年十二月三十一日止年度的年度綜合財務報表所採用者一致，惟於本期間之財務資料首次採納下列經修訂的香港財務報告準則（「香港財務報告準則」）除外。

Amendments to HKFRS 3	<i>Reference to the Conceptual Framework</i>	香港財務報告準則第3號(修訂本)	對概念框架的提述
Amendments to HKAS 16	<i>Property, Plant and Equipment: Proceeds before Intended Use</i>	香港會計準則第16號(修訂本)	物業、廠房及設備：擬定用途前的所得款項
Amendments to HKAS 37	<i>Onerous Contracts – Cost of Fulfilling a Contract</i>	香港會計準則第37號(修訂本)	有價合約—履行合約的成本
Annual Improvements to HKFRSs 2018–2020	Amendments to HKFRS 1, HKFRS 9, Illustrative Examples accompanying 2018–2020 HKFRS 16, and HKAS 41	香港財務報告準則二零一八年至二零二零年週期之年度改進	香港財務報告準則第1號、香港財務報告準則第9號、香港財務報告準則第16號相應闡釋範例及香港會計準則第41號(修訂本)

NOTES TO INTERIM CONDENSED CONSOLIDATED FINANCIAL INFORMATION

中期簡明綜合財務資料附註

For the six months ended 30 June 2022 截至二零二二年六月三十日止六個月

2. BASIS OF PREPARATION AND ACCOUNTING POLICIES – continued 2. 編製基準及會計政策—續

2.2. CHANGES IN ACCOUNTING POLICIES AND DISCLOSURES – continued

The nature and impact of the revised HKFRSs are described below:

- (a) Amendments to HKFRS 3 replace a reference to the previous *Framework for the Preparation and Presentation of Financial Statements* with a reference to the *Conceptual Framework for Financial Reporting* (the “Conceptual Framework”) issued in June 2018 without significantly changing its requirements. The amendments also add to HKFRS 3 an exception to its recognition principle for an entity to refer to the Conceptual Framework to determine what constitutes an asset or a liability. The exception specifies that, for liabilities and contingent liabilities that would be within the scope of HKAS 37 or HK(IFRIC)-Int 21 if they were incurred separately rather than assumed in a business combination, an entity applying HKFRS 3 should refer to HKAS 37 or HK(IFRIC)-Int 21 respectively instead of the Conceptual Framework. Furthermore, the amendments clarify that contingent assets do not qualify for recognition at the acquisition date. The Group has applied the amendments prospectively to business combinations that occurred on or after 1 January 2022. As there was no business combination during the period, the amendments did not have any impact on the financial position and performance of the Group.

2.2. 會計政策及披露變動—續

經修訂香港財務報告準則之性質及影響說明如下：

- (a) 香港財務報告準則第3號(修訂本)以對二零一八年六月發佈的*財務報告概念框架*(「概念框架」)的提述取代對先前*財務報表編製及列報框架*的提述，而無需大幅度改變其要求。該等修訂本亦為香港財務報告準則第3號之確認原則增添了例外，以使企業可利用概念框架作為參考以決定資產或負債的構成。該例外規定，對於在香港會計準則第37號或香港財務報告詮釋委員會21號解釋範圍內發生的負債及或然負債，如果是單獨發生而不是在企業合併中產生的，採用香港財務報告準則第3號的實體應參考香港會計準則第37號或香港財務報告詮釋委員會21號解釋而不是概念框架。此外，該等修訂本闡明或然資產在購買日不符合確認條件。本集團前瞻性地將修訂適用於二零二二年一月一日或之後發生的企業合併。由於期內並無企業合併，因此該等修訂本對本集團的財務狀況及表現並無任何影響。

NOTES TO INTERIM CONDENSED CONSOLIDATED FINANCIAL INFORMATION

中期簡明綜合財務資料附註

For the six months ended 30 June 2022 截至二零二二年六月三十日止六個月

2. BASIS OF PREPARATION AND ACCOUNTING POLICIES – continued 2. 編製基準及會計政策—續

2.2. CHANGES IN ACCOUNTING POLICIES AND DISCLOSURES – continued

(b) Amendments to HKAS 16 prohibit an entity from deducting from the cost of an item of property, plant and equipment any proceeds from selling items produced while bringing that asset to the location and condition necessary for it to be capable of operating in the manner intended by management. Instead, an entity recognises the proceeds from selling any such items, and the cost of those items, in profit or loss. The Group has applied the amendments retrospectively to items of property, plant and equipment made available for use on or after 1 January 2021. Since there was no sale of items produced while making property, plant and equipment available for use on or after 1 January 2021, the amendments did not have any impact on the financial position or performance of the Group.

2.2. 會計政策及披露變動—續

(b) 香港會計準則第16號(修訂本)禁止實體從物業、廠房及設備項目的成本中扣除該資產到能夠以管理層預期的方式運營所需的必要位置及條件過程中透過銷售產生的任何收益。相反，實體應在損益中確認出售任何此類項目的收益以及這些項目的成本。本集團對二零二一年一月一日或之後提供使用的物業、廠房及設備項目追溯應用該等修訂本。由於在二零二一年一月一日或之後使用物業、廠房及設備時並無出售所生產的項目，故該等修訂本對本集團的財務狀況或表現並無任何影響。

NOTES TO INTERIM CONDENSED CONSOLIDATED FINANCIAL INFORMATION

中期簡明綜合財務資料附註

For the six months ended 30 June 2022 截至二零二二年六月三十日止六個月

2. BASIS OF PREPARATION AND ACCOUNTING POLICIES – continued 2. 編製基準及會計政策—續

2.2. CHANGES IN ACCOUNTING POLICIES AND DISCLOSURES – continued

(c) Amendments to HKAS 37 clarify that for the purpose of assessing whether a contract is onerous under HKAS 37, the cost of fulfilling the contract comprises the costs that relate directly to the contract. Costs that relate directly to a contract include both the incremental costs of fulfilling that contract (e.g., direct labour and materials) and an allocation of other costs that relate directly to fulfilling that contract (e.g., an allocation of the depreciation charge for an item of property, plant and equipment used in fulfilling the contract as well as contract management and supervision costs). General and administrative costs do not relate directly to a contract and are excluded unless they are explicitly chargeable to the counterparty under the contract. The Group has applied the amendments prospectively to contracts for which it has not yet fulfilled all its obligations at 1 January 2022 and no onerous contracts were identified. Therefore, the amendments did not have any impact on the financial position or performance of the Group.

2.2. 會計政策及披露變動—續

(c) 香港會計準則第37號(修訂本)闡明，為了評估香港會計準則第37號下的合約是否虧損，履行合約的成本包括與合約直接相關的成本。與合約直接相關的成本包括履行該合約的增量成本(例如直接勞動力和材料)和與履行該合約直接相關的其他成本的分配(例如用於履行合約的物業、廠房及設備的折舊費的分配，以及合約管理及監督的成本)。一般及行政成本與合約沒有直接關係，除非根據合約明確向對方收取，否則不包括在內。本集團前瞻性地將修訂應用於二零二二年一月一日尚未履行其所有義務的合約及尚未識別出虧損合約。因此，該等修訂本對本集團的財務狀況或表現並無任何影響。

NOTES TO INTERIM CONDENSED CONSOLIDATED FINANCIAL INFORMATION

中期簡明綜合財務資料附註

For the six months ended 30 June 2022 截至二零二二年六月三十日止六個月

2. BASIS OF PREPARATION AND ACCOUNTING POLICIES – continued 2. 編製基準及會計政策—續

2.2. CHANGES IN ACCOUNTING POLICIES AND DISCLOSURES – continued

(d) *Annual Improvements to HKFRSs 2018–2020* sets out amendments to HKFRS 1, HKFRS 9, Illustrative Examples accompanying HKFRS 16, and HKAS 41. Details of the amendments that are applicable to the Group are as follows:

- HKFRS 9 *Financial Instruments*: clarifies the fees that an entity includes when assessing whether the terms of a new or modified financial liability are substantially different from the terms of the original financial liability. These fees include only those paid or received between the borrower and the lender, including fees paid or received by either the borrower or lender on the other's behalf. The Group has applied the amendment prospectively to financial liabilities that are modified or exchanged on or after 1 January 2022. As there was no modification of the Group's financial liabilities during the period, the amendment did not have any impact on the financial position or performance of the Group.

2.2. 會計政策及披露變動—續

(d) 香港財務報告準則二零一八年至二零二零年週期之年度改進列出了香港財務報告準則第1號、香港財務報告準則第9號、香港財務報告準則第16號相應闡釋範例及香港會計準則第41號。預計將適用於本集團的修訂本詳情如下：

- 香港財務報告準則第9號金融工具：釐清了實體在評估新的或修改的金融負債條款是否與原始金融負債條款有實質性差異時所包含的費用。該等費用僅包括借款人與貸款人之間支付或收取的費用，包括借款人或貸款人代表對方支付或收取的費用。本集團前瞻性地將修訂本應用於二零二二年一月一日或之後修改或交換的金融負債。由於在此期間集團的金融負債並無修改，因此該修訂本對本集團的財務狀況或表現並無任何影響。

NOTES TO INTERIM CONDENSED CONSOLIDATED FINANCIAL INFORMATION

中期簡明綜合財務資料附註

For the six months ended 30 June 2022 截至二零二二年六月三十日止六個月

2. BASIS OF PREPARATION AND ACCOUNTING POLICIES – continued

2.2. CHANGES IN ACCOUNTING POLICIES AND DISCLOSURES – continued

(d) – continued

- HKFRS 16 *Leases*: removes the illustration of payments from the lessor relating to leasehold improvements in Illustrative Example 13 accompanying HKFRS 16. This removes potential confusion regarding the treatment of lease incentives when applying HKFRS 16.

3. OPERATING SEGMENT INFORMATION

For management purposes, the Group has one single operating and reportable segment, which is the provision of medical care, health care and geriatric care related services and products. All of the Group's operating results are generated from this single segment. During the period, 100% (six months ended 30 June 2021: 100%) of the Group's revenue was generated from customers in Mainland China, and over 77% (as at 31 December 2021: over 78%) of the Group's non-current assets, excluding financial instruments and deferred tax assets, were located in Mainland China.

Revenue of approximately HK\$22,349,000 (six months ended 30 June 2021: HK\$11,017,000) was derived from sales of goods to a single customer, including sales to a group of entities which are known to be under common control with that customer.

2. 編製基準及會計政策－續

2.2. 會計政策及披露變動－續

(d) – 續

- 香港財務報告準則第16號租賃：刪除了香港財務報告準則第16號相應闡釋範例13中出租人償還租賃物業裝修之說明。該消除了應用香港財務報告準則第16號對關於處理租賃獎勵有關的任何潛在混淆情況。

3. 經營分類資料

就管理而言，本集團持有一項持續經營業務之單一營運及可報告分類，即提供醫療、健康及養老相關服務及產品。本集團所有經營業績均源自此單一分類。期內，本集團100%（截至二零二一年六月三十日止六個月：100%）收入由中國大陸的客戶產生，本集團超過77%（於二零二一年十二月三十一日：超過78%）非流動資產（不包括金融工具及遞延稅項資產）乃位於中國大陸。

收入約22,349,000港元（截至二零二一年六月三十日止六個月：11,017,000港元）乃源自向單一客戶銷售貨品，包括向一組已知受該客戶共同控制的實體進行的銷售。

NOTES TO INTERIM CONDENSED CONSOLIDATED FINANCIAL INFORMATION

中期簡明綜合財務資料附註

For the six months ended 30 June 2022 截至二零二二年六月三十日止六個月

4. REVENUE

An analysis of revenue is as follows:

4. 收入

收入分析如下：

		For the six months ended 30 June	
		截至六月三十日止六個月	
		2022	2021
		二零二二年	二零二一年
		HK\$'000	HK\$'000
		千港元	千港元
		(Unaudited)	(Unaudited)
		(未經審核)	(未經審核)
Revenue from contracts with customers	來自客戶合約之收入	91,807	79,619

DISAGGREGATED REVENUE INFORMATION FOR REVENUE FROM CONTRACTS WITH CUSTOMERS

來自客戶合約之收入之細分收入資料

		For the six months ended 30 June	
		截至六月三十日止六個月	
		2022	2021
		二零二二年	二零二一年
		HK\$'000	HK\$'000
		千港元	千港元
		(Unaudited)	(Unaudited)
		(未經審核)	(未經審核)
Types of goods or services	商品或服務類型		
Sales of goods	銷售商品	88,126	75,662
Rendering of services	提供服務	3,681	3,957
Total revenue from contracts with customers	來自客戶合約之總收入	91,807	79,619

NOTES TO INTERIM CONDENSED CONSOLIDATED FINANCIAL INFORMATION

中期簡明綜合財務資料附註

For the six months ended 30 June 2022 截至二零二二年六月三十日止六個月

4. REVENUE – continued

DISAGGREGATED REVENUE INFORMATION FOR REVENUE FROM CONTRACTS WITH CUSTOMERS – continued

The Group's revenue arising from sale of goods is recognised when transferred at a point in time, while revenue arising from rendering of services is recognised when transferred over time.

4. 收入－續

來自客戶合約之收入之細分收入資料－續

本集團銷售商品產生的收入於某一時間點轉讓確認，而提供服務產生的收入隨時間轉讓確認。

For the six months ended 30 June

截至六月三十日止六個月

2022	2021
二零二二年	二零二一年
HK\$'000	HK\$'000
千港元	千港元
(Unaudited)	(Unaudited)
(未經審核)	(未經審核)

Geographical markets	地域市場		
Mainland China	中國內地	91,807	79,619
Total revenue from contracts with customers	來自客戶合約之總收入	91,807	79,619

NOTES TO INTERIM CONDENSED CONSOLIDATED FINANCIAL INFORMATION

中期簡明綜合財務資料附註

For the six months ended 30 June 2022 截至二零二二年六月三十日止六個月

5. OTHER INCOME AND GAINS, NET

An analysis of the Group's other income and gains, net are as follows:

5. 其他收入及收益淨額

本集團之其他收入及收益淨額分析如下：

		For the six months ended 30 June 截至六月三十日止六個月	
		2022 二零二二年 HK\$'000 千港元 (Unaudited) (未經審核)	2021 二零二一年 HK\$'000 千港元 (Unaudited) (未經審核)
Other income	其他收入		
Bank interest income	銀行利息收入	444	2,469
Other interest income	其他利息收入	6,520	11,116
Investment income of debt investment at fair value through other comprehensive income	透過其他全面收益以公平值列賬之債權投資之投資收入	1,561	2,037
Investment income of equity investments designated at fair value through other comprehensive income	指定為透過其他全面收益以公平值列賬之權益投資之投資收入	1,430	1,084
Investment income of financial assets at fair value through profit or loss	透過損益以公平值列賬之金融資產之投資收入	1,241	-
Gross rental income from investment property under operating lease	來自經營租賃下的投資物業的租金收入總額	6,575	4,593
Dividend income	股息收入	1,114	1,246
Sundry income	雜項收入	415	789
		19,300	23,334
Gains, net	收益淨額		
Gain on disposal of property, plant and equipment	出售物業、廠房及設備的收益	67	-
Fair value losses on investment properties, net	投資物業之公平值虧損淨額	(2,656)	(959)
Fair value losses on financial assets at fair value through profit or loss, net	透過損益以公平值列賬之金融資產之公平值虧損淨額	(566)	(3,022)
Gain on deconsolidation of a subsidiary	一間附屬公司不再綜合入賬的收益	63	-
Gain on disposal of an associate	出售一間聯營公司的收益	858	-
Gain on disposal of equity investment designated at fair value through other comprehensive income	出售指定為透過其他全面收益以公平值列賬之權益投資之收益	1,410	-
Gain on redemption of debt investment at fair value through other comprehensive income	贖回透過其他全面收益以公平值列賬之債權投資之收益	4,375	-
Foreign exchange differences, net	匯兌差額淨額	-	8,576
Reversal of impairment loss on investment in an associate	撥回於一間聯營公司之投資的減值虧損	-	13,527
		3,551	18,122
Other income and gains, net	其他收入及收益淨額	22,851	41,456

NOTES TO INTERIM CONDENSED CONSOLIDATED FINANCIAL INFORMATION

中期簡明綜合財務資料附註

For the six months ended 30 June 2022 截至二零二二年六月三十日止六個月

6. FINANCE COSTS

An analysis of finance costs is as follows:

6. 融資成本

融資成本之分析如下：

		For the six months ended 30 June	
		截至六月三十日止六個月	
		2022	2021
		二零二二年	二零二一年
		HK\$'000	HK\$'000
		千港元	千港元
		(Unaudited)	(Unaudited)
		(未經審核)	(未經審核)
Interest on bank borrowings	銀行借款之利息	263	645
Interest on lease liabilities	租賃負債利息	339	304
		602	949

NOTES TO INTERIM CONDENSED CONSOLIDATED FINANCIAL INFORMATION

中期簡明綜合財務資料附註

For the six months ended 30 June 2022 截至二零二二年六月三十日止六個月

7. LOSS BEFORE TAX

The Group's loss before tax is arrived at after charging/(crediting):

7. 除稅前虧損

本集團之除稅前虧損已扣除／(計入)下列各項後計算：

		For the six months ended 30 June	
		截至六月三十日止六個月	
		2022	2021
		二零二二年	二零二一年
		HK\$'000	HK\$'000
		千港元	千港元
		(Unaudited)	(Unaudited)
		(未經審核)	(未經審核)
Cost of inventories sold	已售存貨成本	64,363	54,715
Cost of services provided	提供服務成本	2,190	2,350
Depreciation of property, plant and equipment	物業、廠房及設備折舊	3,168	5,610
Depreciation of right-of-use assets	使用權資產折舊	10,974	11,768
Foreign exchange differences, net	匯兌差額淨額	1,676*	(8,576)
Impairment of financial assets:	金融資產減值：		
Impairment of trade receivables	應收貿易賬款減值	2,849	1,106
Gain on disposal of an associate	出售一間聯營公司的收益	(858)	—
Gain on deconsolidation of a subsidiary	一間附屬公司不再綜合入賬的收益	(63)	—
Loss on deemed partial disposal of an associate [#]	視作部分出售一間聯營公司的虧損 [#]	—	5,291

* These items are included in "Other expenses and losses" on the face of the condensed consolidated statement of profit or loss and other comprehensive income.

* 該等項目計入簡明綜合損益及其他全面收益表內的「其他開支及虧損」中。

NOTES TO INTERIM CONDENSED CONSOLIDATED FINANCIAL INFORMATION

中期簡明綜合財務資料附註

For the six months ended 30 June 2022 截至二零二二年六月三十日止六個月

8. INCOME TAX CREDIT

8. 所得稅抵免

For the six months ended 30 June

截至六月三十日止六個月

2022	2021
二零二二年	二零二一年
HK\$'000	HK\$'000
千港元	千港元
(Unaudited)	(Unaudited)
(未經審核)	(未經審核)

Current	即期		
PRC corporate income tax	中國企業所得稅		
Charge for the period	期內支出	2,255	287
Overprovision in prior periods	過往期間超額撥備	-	(5,677)
Deferred	遞延	(3,541)	(1,200)
Total tax credit for the period	期內稅項抵免總額	(1,286)	(6,590)

HONG KONG PROFITS TAX

No provision for Hong Kong profits tax had been made as the Group did not generate any assessable profits in Hong Kong during the period (six months ended 30 June 2021: Nil).

PRC CORPORATE INCOME TAX

PRC corporate income tax provision in respect of operations in Mainland China is calculated at the applicable tax rates on the estimated assessable profits for the period based on prevailing legislation, interpretations and practices in respect thereof.

香港利得稅

由於本集團期內並無於香港產生任何應課稅溢利，故並無就香港利得稅作出撥備(截至二零二一年六月三十日止六個月：無)。

中國企業所得稅

有關中國內地營運的中國企業所得稅撥備乃根據相關現行法例、詮釋及常規按期內估計應課稅溢利的適用稅率計算。

NOTES TO INTERIM CONDENSED CONSOLIDATED FINANCIAL INFORMATION

中期簡明綜合財務資料附註

For the six months ended 30 June 2022 截至二零二二年六月三十日止六個月

9. DIVIDEND

The directors of the Company do not recommend any payment of interim dividend to shareholders for the six months ended 30 June 2022 (six months ended 30 June 2021: Nil).

10. LOSS PER SHARE ATTRIBUTABLE TO OWNERS OF THE COMPANY

The calculation of the basic loss per share amount is based on the unaudited loss for the period attributable to ordinary equity holders of the parent of HK\$32,820,000 (six months ended 30 June 2021: HK\$12,318,000), and the weighted average number of ordinary shares of 6,078,944,027 (six months ended 30 June 2021: 6,078,944,027) in issue during the period.

No adjustment has been made to the basic loss per share amounts presented for the six months ended 30 June 2022 and 30 June 2021 in respect of a dilution as the share options outstanding had no diluting effect on the basic loss per share amounts presented.

11. PROPERTY, PLANT AND EQUIPMENT

During the period, the Group acquired property, plant and equipment at an aggregate cost of HK\$904,000 (six months ended 30 June 2021: HK\$2,250,000).

During the period, the Group disposed of property, plant and equipment with an aggregate net book value of HK\$37,000 (six months ended 30 June 2021: HK\$19,000), resulting a net gain on disposal of HK\$67,000 (six months ended 30 June 2021: HK\$Nil).

9. 股息

本公司董事並不建議向股東派付截至二零二二年六月三十日止六個月之中期股息(截至二零二一年六月三十日止六個月：無)。

10. 本公司擁有人應佔每股虧損

每股基本虧損乃按照母公司普通股權益持有人應佔期內未經審核虧損32,820,000港元(截至二零二一年六月三十日止六個月：12,318,000港元)，及期內已發行普通股之加權平均數6,078,944,027股(截至二零二一年六月三十日止六個月：6,078,944,027股)計算。

由於未行使購股權對所呈列的每股基本虧損金額並無攤薄效應，故此並無就攤薄對截至二零二二年六月三十日及二零二一年六月三十日止六個月呈列的每股基本虧損金額作出調整。

11. 物業、廠房及設備

期內，本集團收購物業、廠房及設備，總成本為904,000港元(截至二零二一年六月三十日止六個月：2,250,000港元)。

期內，本集團出售賬面淨值合共為37,000港元(截至二零二一年六月三十日止六個月：19,000港元)的物業、廠房及設備，產生出售收益淨額67,000港元(截至二零二一年六月三十日止六個月：零港元)。

NOTES TO INTERIM CONDENSED CONSOLIDATED FINANCIAL INFORMATION

中期簡明綜合財務資料附註

For the six months ended 30 June 2022 截至二零二二年六月三十日止六個月

12. TRADE AND BILLS RECEIVABLES

An ageing analysis of the trade receivables as at the end of the reporting period, based on the invoice date and net of loss allowance, is as follows:

12. 應收貿易賬款及應收票據

於報告期末，應收貿易賬款按發票日期及扣除虧損撥備的賬齡分析如下：

		30 June 2022 二零二二年 六月 三十日 HK\$'000 千港元 (Unaudited) (未經審核)	31 December 2021 二零二一年 十二月 三十一日 HK\$'000 千港元 (Audited) (經審核)
Trade receivables:	應收貿易賬款：		
Within 6 months	六個月內	27,291	11,646
7 to 12 months	七至十二個月	11,945	15,589
13 to 18 months	十三至十八個月	1,623	2,529
19 to 24 months	十九至二十四個月	1,429	5,035
		42,288	34,799
Bills receivables	應收票據	117	-
		42,405	34,799

NOTES TO INTERIM CONDENSED CONSOLIDATED FINANCIAL INFORMATION

中期簡明綜合財務資料附註

For the six months ended 30 June 2022 截至二零二二年六月三十日止六個月

13. TRADE PAYABLES

An ageing analysis of the trade payables as at the end of the reporting period, based on the invoice date, is as follows:

13. 應付貿易賬款

於報告期末，應付貿易賬款按發票日期的賬齡分析如下：

		30 June 2022 二零二二年 六月 三十日 HK\$'000 千港元 (Unaudited) (未經審核)	31 December 2021 二零二一年 十二月 三十一日 HK\$'000 千港元 (Audited) (經審核)
Within 3 months	三個月內	22,433	26,170
Over 3 months	三個月以上	15,950	20,254
		38,383	46,424

The trade payables are non-interest-bearing and are normally settled on terms of 3 to 6 months.

應付貿易賬款為不計息，通常按三至六個月之期限結算。

NOTES TO INTERIM CONDENSED CONSOLIDATED FINANCIAL INFORMATION

中期簡明綜合財務資料附註

For the six months ended 30 June 2022 截至二零二二年六月三十日止六個月

14. SHARE CAPITAL

14. 股本

		30 June 2022 二零二二年 六月 三十日 HK\$'000 千港元 (Unaudited) (未經審核)	31 December 2021 二零二一年 十二月 三十一日 HK\$'000 千港元 (Audited) (經審核)
Authorised:	法定：		
10,000,000,000	10,000,000,000股		
(31 December 2021:	(二零二一年		
10,000,000,000) ordinary	十二月三十一日：		
shares of HK\$0.2 each	10,000,000,000股)		
	每股面值0.2港元之		
	普通股	2,000,000	2,000,000
Issued and fully paid:	已發行及繳足：		
6,078,944,027	6,078,944,027股		
(31 December 2021:	(二零二一年		
6,078,944,027) ordinary	十二月三十一日：		
shares of HK\$0.2 each	6,078,944,027股)		
	每股面值0.2港元之		
	普通股	1,215,789	1,215,789

NOTES TO INTERIM CONDENSED CONSOLIDATED FINANCIAL INFORMATION

中期簡明綜合財務資料附註

For the six months ended 30 June 2022 截至二零二二年六月三十日止六個月

15. SHARE-BASED COMPENSATION SCHEMES 15. 以股份支付的補償計劃

The Company first adopted a share option scheme effective from 26 April 2002 (the “2002 Scheme”) and which has been expired in April 2012. On 24 May 2013, the Company adopted a new share option scheme (the “2013 Scheme”) to replace the 2002 Scheme. The eligible participants and the terms of the 2013 Scheme is the same as 2002 Scheme. There is no movement of share options under the 2013 Scheme during the period.

The exercise prices and exercise periods of the share options outstanding at 30 June 2022 and 31 December 2021 are as follows:

30 June 2022 二零二二年 六月三十日	31 December 2021 二零二一年 十二月三十一日	Exercise price per share 每股行使價	Exercise period per share 每股行使期
Number of options 購股權數目	Number of options 購股權數目	HK\$ 港元	HK\$ 港元
'000 千份	'000 千份	(note (c)) (附註(c))	(note (c)) (附註(c))
166,500	166,500	0.61	note (a) 附註(a)
111,500	111,500	0.53	note (b) 附註(b)
278,000	278,000		

本公司於二零零二年四月二十六日首次採納一項購股權計劃(「二零零二年計劃」)，而該計劃已於二零一二年四月屆滿。於二零一三年五月二十四日，本公司採納新購股權計劃(「二零一三年計劃」)以取代二零零二年計劃。二零一三年計劃之合資格參與者及條款與二零零二年計劃相同。期內，二零一三年計劃項下之購股權並無變動。

於二零二二年六月三十日及二零二一年十二月三十一日尚未行使的購股權之行使價及行使期如下：

NOTES TO INTERIM CONDENSED CONSOLIDATED FINANCIAL INFORMATION

中期簡明綜合財務資料附註

For the six months ended 30 June 2022 截至二零二二年六月三十日止六個月

15. SHARE-BASED COMPENSATION SCHEMES

– continued

Notes:

- (a) First 30% of the options granted were vested from 2 April 2016, second 30% of the options granted were vested from 2 April 2017 and remaining 40% of the options granted were vested from 2 April 2018. Upon the lapse of the vesting period, the share options are exercisable until 1 April 2025.
- (b) First 30% of the options granted were vested from 28 January 2017, second 30% of the options granted were vested from 28 January 2018 and remaining 40% of the options granted were vested from 28 January 2019. Upon the lapse of the vesting period, the share options are exercisable until 27 January 2026.
- (c) The exercise price of the share options is subject to adjustment in the case of rights or bonus issues, or other similar changes in the Company's share capital.

During the period, the Group did not recognise any share option expense in respect of the share option granted (six months ended 30 June 2021: Nil).

At the end of the reporting period, the Company had 278,000,000 share options outstanding. The exercise in full of the outstanding share options would, under the present capital structure of the Company, result in the issue of 278,000,000 additional ordinary shares of the Company, which represented approximately 4.6% of the Company's shares in issue as at that date, and additional share capital of HK\$55,600,000 and share premium of HK\$105,060,000 (before issue expenses).

15. 以股份支付的補償計劃一續

附註：

- (a) 首30%已授出購股權自二零一六年四月二日起歸屬，第二批30%已授出購股權自二零一七年四月二日起歸屬，而餘下40%已授出購股權自二零一八年四月二日起歸屬。於歸屬期失效後，購股權於二零二五年四月一日前均可予行使。
- (b) 首30%已授出購股權自二零一七年一月二十八日起歸屬，第二批30%已授出購股權自二零一八年一月二十八日起歸屬，而餘下40%已授出購股權自二零一九年一月二十八日起歸屬。於歸屬期失效後，購股權於二零二六年一月二十七日前均可予行使。
- (c) 購股權之行使價可根據供股或發行紅股或本公司股本之其他類似變動而予以調整。

於期內，本集團並無就已授出的購股權確認任何購股權開支（截至二零二一年六月三十日止六個月：無）。

於報告期末，本公司有278,000,000份尚未行使購股權。根據本公司現行資本結構，全數行使尚未行使的購股權將導致發行278,000,000股本公司額外普通股，佔本公司於該日已發行股份約4.6%，以及增加55,600,000港元的股本及105,060,000港元的股份溢價（未計發行開支）。

NOTES TO INTERIM CONDENSED CONSOLIDATED FINANCIAL INFORMATION

中期簡明綜合財務資料附註

For the six months ended 30 June 2022 截至二零二二年六月三十日止六個月

16. DECONSOLIDATION OF A SUBSIDIARY

On 15 June 2022, the Group lost control over Guangzhou Jinfu City Fund (limited partnership)* and hence they have been accounted for as an associate of the Group since then.

16. 一間附屬公司不再綜合入賬

於二零二二年六月十五日，本集團失去對廣州金富城發股權投資基金合夥企業(有限合夥)的控制權，因此該等自此作為本集團的聯營公司入賬。

**For the
six months
ended
30 June
2022
截至
二零二二年
六月三十日止
六個月
HK\$'000
千港元
(Unaudited)
(未經審核)**

Net assets deconsolidated of:	已不再綜合入賬的資產淨值：	
Equity investments designated at fair value through other comprehensive income	指定為透過其他全面收益以公平值列賬之權益投資	75,166
Prepayments, other receivables and other assets	預付款項、其他應收款項及其他資產	7
Cash and cash equivalents	現金及現金等值物	19,335
Other payables and accruals	其他應付款項及應計費用	(25)
Non-controlling interests	非控股權益	(71,156)
		23,327
Exchange fluctuation reserve	匯兌波動儲備	(48)
		23,279
Gain on deconsolidation of subsidiary	一間附屬公司不再綜合入賬的收益	63
		23,342
Satisfied by:	以下列方式償付：	
Fair value of interests retained by the Group	本集團保留權益之公平值	23,342

* For identification purpose only

* 僅供識別

NOTES TO INTERIM CONDENSED CONSOLIDATED FINANCIAL INFORMATION

中期簡明綜合財務資料附註

For the six months ended 30 June 2022 截至二零二二年六月三十日止六個月

16. DECONSOLIDATION OF A SUBSIDIARY – 16. 一間附屬公司不再綜合入賬 – 續

An analysis of the net outflow of cash and cash equivalents in respect of the deconsolidation of a subsidiary is as follows:

一間附屬公司不再綜合入賬的現金及現金等值物淨流出分析如下：

For the
six months
ended
30 June
2022
截至
二零二二年
六月三十日止
六個月
HK\$'000
千港元
(Unaudited)
(未經審核)

Cash and cash equivalents deconsolidated of and net outflow of cash and cash equivalents in respect of the deconsolidation of a subsidiary	已不再綜合入賬的現金及現金等值物及一間附屬公司不再綜合入賬的現金及現金等值物淨流出	(19,335)
--	---	----------

NOTES TO INTERIM CONDENSED CONSOLIDATED FINANCIAL INFORMATION

中期簡明綜合財務資料附註

For the six months ended 30 June 2022 截至二零二二年六月三十日止六個月

17. PLEDGE OF ASSETS

As at 30 June 2022, the following assets were pledged to secure the banking facilities granted to the Group:

17. 資產抵押

於二零二二年六月三十日，已抵押以下資產，作為本集團獲授銀行授信之擔保：

		30 June 2022 二零二二年 六月 三十日 HK\$'000 千港元 (Unaudited) (未經審核)	31 December 2021 二零二一年 十二月 三十一日 HK\$'000 千港元 (Audited) (經審核)
Property, plant and equipment	物業、廠房及設備	24,348	26,363
Investment properties	投資物業	31,560	32,642
Right-of-use assets	使用權資產	–	383,084
Equity investments designated at fair value through other comprehensive income	指定為透過其他全面 收益以公平值列賬 之權益投資	29,715	–
Financial assets at fair value through profit or loss	透過損益以公平值列賬 之金融資產	3,341	–
Cash and cash equivalents	現金及現金等值物	4,120	–
		93,084	442,089

NOTES TO INTERIM CONDENSED CONSOLIDATED FINANCIAL INFORMATION

中期簡明綜合財務資料附註

For the six months ended 30 June 2022 截至二零二二年六月三十日止六個月

18. CONTINGENT LIABILITIES

The Group has contingent liabilities up to RMB28,000,000 (equivalent to approximately HK\$32,741,000) as a guarantor for the bank facility granted to an associate of the Company (31 December 2021: RMB28,000,000 (equivalent to approximately HK\$34,247,000)).

As at 30 June 2022, the associate has utilized bank loans of approximately RMB26,554,000 (equivalent to approximately HK\$31,050,000) which is guaranteed by the Group (31 December 2021: approximately RMB26,386,000 (equivalent to approximately HK\$32,273,000)).

Save as disclosed above, the Group has no significant contingent liabilities as at 30 June 2022.

19. COMMITMENTS

The Group had the following capital commitments at 30 June 2022 and 31 December 2021:

18. 或然負債

本集團就授予本公司一間聯營公司之銀行融資作為擔保人，擁有或然負債最多人民幣28,000,000元(相當於約32,741,000港元)，(二零二一年十二月三十一日：人民幣28,000,000元(相當於約34,247,000港元))。

於二零二二年六月三十日，該聯營公司已動用由本集團提供擔保的銀行貸款約人民幣26,554,000(相當於31,050,000港元)，(二零二一年十二月三十一日：約人民幣26,386,000元(相當於約32,273,000港元))。

除上文披露者外，於二零二一年六月三十日，本集團並無重大或然負債。

19. 承擔

本集團於二零二二年六月三十日及二零二一年十二月三十一日有以下資本承擔：

	30 June 2022 二零二二年 六月 三十日 HK\$'000 千港元 (Unaudited) (未經審核)	31 December 2021 二零二一年 十二月 三十一日 HK\$'000 千港元 (Audited) (經審核)
Contracted, but not provided for: 已訂約但未撥備：		
Land and buildings 土地及樓宇	59,152	61,786
Property under development 發展中物業	22,786	23,076
	81,938	84,862

NOTES TO INTERIM CONDENSED CONSOLIDATED FINANCIAL INFORMATION

中期簡明綜合財務資料附註

For the six months ended 30 June 2022 截至二零二二年六月三十日止六個月

20. RELATED PARTY DISCLOSURES

Compensation of key management personnel of the Group:

20. 關聯方披露

本集團主要管理人員之補償：

		For the six months ended 30 June	
		截至六月三十日止六個月	
		2022	2021
		二零二二年	二零二一年
		HK\$'000	HK\$'000
		千港元	千港元
		(Unaudited)	(Unaudited)
		(未經審核)	(未經審核)
Salaries, allowances and benefits in kind	薪金、津貼及實物福利	2,200	3,665
Performance related bonuses	表現相關花紅	-	117
Pension scheme contributions	退休金計劃供款	100	98
		2,300	3,880

NOTES TO INTERIM CONDENSED CONSOLIDATED FINANCIAL INFORMATION

中期簡明綜合財務資料附註

For the six months ended 30 June 2022 截至二零二二年六月三十日止六個月

21. FAIR VALUE AND FAIR VALUE HIERARCHY OF FINANCIAL INSTRUMENTS

The carrying amounts and fair values of the Group's financial instruments, other than those financial assets and financial liabilities where their fair values approximate to their carrying amounts such that no disclosure of the fair values of these financial instruments is made, are as follows:

21. 金融工具之公平值及公平值層級

本集團的金融工具(該等公平值與其賬面值相若之金融資產及金融負債除外，故此並無披露該等金融工具之公平值)之賬面值與公平值列示如下：

	Carrying amounts		Fair values	
	賬面值		公平值	
	30 June	31 December	30 June	31 December
	2022	2021	2022	2021
	二零二二年	二零二一年	二零二二年	二零二一年
	六月三十日	十二月三十一日	六月三十日	十二月三十一日
	HK\$'000	HK\$'000	HK\$'000	HK\$'000
	千港元	千港元	千港元	千港元
	(Unaudited)	(Audited)	(Unaudited)	(Audited)
	(未經審核)	(經審核)	(未經審核)	(經審核)
Financial assets	金融資產			
Equity investments designated at fair value through other comprehensive income	指定為透過其他全面收益按公平值計量的權益投資			
	234,192	323,881	234,192	323,881
Debt investment at fair value through other comprehensive income	按公平值計入其他全面收益的債權投資			
	-	40,331	-	40,331
Bills receivables	應收票據			
	117	-	117	-
Financial assets at fair value through profit or loss	透過損益按公平值計量的金融資產			
	340,759	253,169	340,759	253,169
	575,068	617,381	575,068	617,381

NOTES TO INTERIM CONDENSED CONSOLIDATED FINANCIAL INFORMATION

中期簡明綜合財務資料附註

For the six months ended 30 June 2022 截至二零二二年六月三十日止六個月

21. FAIR VALUE AND FAIR VALUE HIERARCHY OF FINANCIAL INSTRUMENTS – continued

Management has assessed that the fair values of cash and cash equivalents, restricted bank balances, trade receivables, trade payables, financial assets included in prepayments, other receivables and other assets, financial liabilities included in other payables and accruals and interest-bearing bank borrowings approximate to their carrying amounts largely due to the short term maturities of these instruments.

The fair values of the financial assets and liabilities are included at the amount at which the instrument could be exchanged in a current transaction between willing parties, other than in a forced or liquidation sale. The following methods and assumptions were used to estimate the fair values:

The fair values of listed equity and debt investments are based on quoted market prices. The fair values of redeemable wealth management products included in financial assets at fair value through profit or loss are based on their quoted market prices. The fair values of non-redeemable wealth management products included in financial assets at fair value through profit or loss have been determined by a discounted cash flow valuation model based on the market interest rates of instruments with similar terms and risks. The fair values of the fund investments are based on quotations provided by the relevant institutions. The fair values of derivative instruments are estimated using binomial tree model with the underlying equity value determined under the market approach or income approach. The binomial tree model incorporates various inputs including risk-free interest rate, volatilities

21. 金融工具之公平值及公平值層級－續

管理層已評估現金及現金等值物、受限制銀行結餘、應收貿易賬款、應付貿易賬款、計入預付款項、其他應收款項及其他資產的金融資產、計入其他應付款項及應計費用的金融負債以及計息銀行借款的公平值與其賬面值相若，主要原因是該等工具的到期年期短。

除被迫或清盤出售外，金融資產及負債的公平值是由自願訂約方之間進行現有交易中該工具之可交換金額。以下方法及假設已用於估計公平值：

上市權益及債權投資的公平值按所報市價計算。計入透過損益按公平值計量的金融資產的可贖回理財產品的公平值按其所報市價計算。透過損益以公平值列賬之金融資產的不可贖回財富管理產品之公平值已透過使用貼現現金流量估值模型釐定，該模型以具有類似條款及風險的工具之市場利率為依據。基金投資的公平值按有關機構所提供的報價計算。衍生工具的公平值使用市場法及收入法項下之二項式模式連同相關已釐定股權價值進行估計。二項式模式納入各項輸入數據(包括無風險利率、波幅及收益率)。指定為透過其他全面收益以公平值列賬之非上市股權投資公平值

NOTES TO INTERIM CONDENSED CONSOLIDATED FINANCIAL INFORMATION

中期簡明綜合財務資料附註

For the six months ended 30 June 2022 截至二零二二年六月三十日止六個月

21. FAIR VALUE AND FAIR VALUE HIERARCHY OF FINANCIAL INSTRUMENTS – continued

and dividends yield. The fair value of an unlisted equity investment designated at fair value through other comprehensive income is based on the quoted market prices of listed investment and the carrying amounts of monetary assets/liabilities held by that unlisted equity investment. The fair value of an unlisted investment at fair value through profit or loss is based on the external transaction in the investee's equity, such as a fresh issue of equity. The fair values of other unlisted equity investments designated at fair value through other comprehensive income or through profit or loss have been estimated using a market approach based on assumptions that are not supported by observable market prices or rates. The valuation requires the directors to determine comparable public companies (peers) based on industry, size and strategy, and calculates an appropriate price multiple, such as the price to book value ("P/B") multiple, or price to earnings ("P/E"), for each comparable company identified. The multiple is calculated by dividing the enterprise value of the comparable company by an asset measure or by an earnings measure, respectively. The valuation is then discounted for considerations such as lack of marketability of the target companies based on company-specific facts and circumstances. The directors believe that the estimated fair values resulting from the valuation technique, which are recorded in the consolidated statement of financial position, and the related changes in fair values, which are recorded in the consolidated statements of profit or loss and other comprehensive income, are reasonable, and that they were the most appropriate values at the end of the reporting period.

21. 金融工具之公平值及公平值層級一續

乃基於上市投資所報市價及該非上市股權投資所持貨幣資產／負債之賬面值。透過損益以公平值列賬之非上市投資公平值乃基於被投資企業股權的外部交易，如新發行股權。其他指定為透過其他全面收益或透過損益以公平值列賬之該非上市股權投資公平值已採用市場法估算，並假設並無可觀察市價或比率所支持。有關估值要求董事根據行業、規模及策略釐定可資比較公眾公司（同業），並計算各已識別的可資比較公司之合適價格倍數（例如市賬率（「市賬率」）倍數或市盈率（「市盈率」））。有關倍數乃按可資比較公司的企業價值分別除以資產措施或收益措施計算。有關估值其後根據公司具體的事實及情況按目標公司之間的流動性等考慮因素貼現。董事相信，估值方法得出的估計公平值（於綜合財務狀況表入賬）及公平值的相關變動（於綜合損益及其他全面收益表中入賬）屬合理，並為本報告期末最恰當的估值。

NOTES TO INTERIM CONDENSED CONSOLIDATED FINANCIAL INFORMATION

中期簡明綜合財務資料附註

For the six months ended 30 June 2022 截至二零二二年六月三十日止六個月

21. FAIR VALUE AND FAIR VALUE HIERARCHY OF FINANCIAL INSTRUMENTS – continued

The fair values of the non-current portion of other payables have been calculated by discounting the expected future cash flows using rates currently available for instruments with similar terms, credit risk and remaining maturities. The changes in fair value as a result of the Group's non-performance risk for the non-current portion of other payables as at 30 June 2022 were assessed to be insignificant.

Below is a summary of significant unobservable inputs to the valuation of financial quantitative sensitivity analysis as at 30 June 2022 and 31 December 2021:

21. 金融工具之公平值及公平值層級一續

其他應付款項非流動部分之公平值已透過使用目前具有類似條款、信用風險及剩餘到期年期的工具之市場利率貼現預期未來現金流量計算。於二零二二年六月三十日，本集團對其他應付款項非流動部分的不履約風險導致之公平值變動被評定為非重大。

以下為於二零二二年六月三十日及二零二一年十二月三十一日財務定量敏感度分析估值的重大不可觀察輸入值概要：

	Valuation technique 估值技術	Significant unobservable input 重大不可觀察輸入值	Range 幅度	Sensitivity of fair value to the input 公平值對輸入值之敏感度
Unlisted equity investments 非上市權益投資	Valuation multiples 估值倍數	Average P/B multiple of peers 同業的平均市賬率倍數	30 June 2022: 1.52 to 4.5744 (31 December 2021: 1.7240 to 6.6567) 二零二二年六月三十日：1.52至4.5744 (二零二一年十二月三十一日：1.7240至6.6567)	5% (31 December 2021: 5%) increase/decrease in multiple would result in increase/decrease in fair value by HK\$753,000 to HK\$3,630,000 (31 December 2021: HK\$1,042,000 to HK\$4,026,000) 倍數上升/下降5% (二零二一年十二月三十一日：5%) 將導致公平值增加/減少753,000港元至3,630,000港元 (二零二一年十二月三十一日：1,042,000港元至4,026,000港元)
		Discount for lack of marketability 缺乏市場流通性折讓	30 June 2022: 32% to 34% (31 December 2021: 32% to 34%) 二零二二年六月三十日：32%至34% (二零二一年十二月三十一日：32%至34%)	1% (31 December 2021: 1%) increase/decrease in discount would result in decrease/increase in fair value by HK\$228,000 to HK\$1,068,000 (31 December 2021: HK\$316,000 to HK\$1,184,000) 折讓上升/下降1% (二零二一年十二月三十一日：1%) 將導致公平值減少/增加228,000港元至1,068,000港元 (二零二一年十二月三十一日：316,000港元至1,184,000港元)

NOTES TO INTERIM CONDENSED CONSOLIDATED FINANCIAL INFORMATION

中期簡明綜合財務資料附註

For the six months ended 30 June 2022 截至二零二二年六月三十日止六個月

21. FAIR VALUE AND FAIR VALUE HIERARCHY OF FINANCIAL INSTRUMENTS – continued FAIR VALUE HIERARCHY

The following tables illustrate the fair value measurement hierarchy of the Group's financial instruments:

21. 金融工具之公平值及公平值層級－續

公平值層級

下表說明本集團之金融工具之公平值計量層級：

		Fair value measurement using 使用以下輸入值以公平值計量			
		Quoted prices in active markets (Level 1)	Significant observable inputs (Level 2)	Significant unobservable inputs (Level 3)	Total
		活躍 市場報價 (第一級)	重大可觀察 輸入值 (第二級)	重大不可觀察 輸入值 (第三級)	總計
		HK\$'000	HK\$'000	HK\$'000	HK\$'000
		千港元	千港元	千港元	千港元
		(Unaudited)	(Unaudited)	(Unaudited)	(Unaudited)
		(未經審核)	(未經審核)	(未經審核)	(未經審核)
As at 30 June 2022	於二零二二年六月三十日				
Equity investments designated at fair value through other comprehensive income	指定為透過其他全面收益以 公平值列賬之權益投資	35,313	198,879	-	234,192
Bills receivables	應收票據	117	-	-	117
Financial assets at fair value through profit or loss	透過損益以公平值列賬之 金融資產	7,836	315,691	17,232	340,759
		43,266	514,570	17,232	575,068

NOTES TO INTERIM CONDENSED CONSOLIDATED FINANCIAL INFORMATION

中期簡明綜合財務資料附註

For the six months ended 30 June 2022 截至二零二二年六月三十日止六個月

21. FAIR VALUE AND FAIR VALUE HIERARCHY OF FINANCIAL INSTRUMENTS – continued FAIR VALUE HIERARCHY – continued

21. 金融工具之公平值及公平值層級 – 續 公平值層級 – 續

		Fair value measurement using 使用以下輸入值以公平值計量			
		Quoted prices in active markets (Level 1)	Significant observable inputs (Level 2)	Significant unobservable inputs (Level 3)	Total
		活躍 市場報價 (第一級)	重大可觀察 輸入值 (第二級)	重大不可觀察 輸入值 (第三級)	總計
		HK\$'000 千港元 (Audited) (經審核)	HK\$'000 千港元 (Audited) (經審核)	HK\$'000 千港元 (Audited) (經審核)	HK\$'000 千港元 (Audited) (經審核)
As at 31 December 2021	於二零二一年 十二月三十一日				
Equity investments designated at fair value through other comprehensive income	指定為透過其他全面收益以 公平值列賬之權益投資	40,619	195,189	88,073	323,881
Debt investment at fair value through other comprehensive income	按公平值計入其他全面收益的 債權投資	40,331	-	-	40,331
Financial assets at fair value through profit or loss	透過損益以公平值列賬之 金融資產	5,948	224,614	22,607	253,169
		86,898	419,803	110,680	617,381

NOTES TO INTERIM CONDENSED CONSOLIDATED FINANCIAL INFORMATION

中期簡明綜合財務資料附註

For the six months ended 30 June 2022 截至二零二二年六月三十日止六個月

21. FAIR VALUE AND FAIR VALUE HIERARCHY OF FINANCIAL INSTRUMENTS – continued

FAIR VALUE HIERARCHY – continued

The movements in fair value measurements within Level 3 during the period are as follows:

21. 金融工具之公平值及公平值層級－續

公平值層級－續

於期內，第三級公平值計量的變動如下：

		30 June 2022	31 December 2021
		二零二二年 六月 三十日	二零二一年 十二月 三十一日
		HK\$'000	HK\$'000
		千港元	千港元
		(Unaudited)	(Audited)
		(未經審核)	(經審核)
Equity investments at fair value through other comprehensive income:	透過其他全面收益以公平值列賬之權益投資：		
At 1 January	於一月一日	88,073	74,150
Total (losses)/gains recognised in other comprehensive income	於其他全面收益確認之總(虧損)/收益	(9,337)	11,566
Deemed disposal upon deconsolidation of a subsidiary	一間附屬公司不再綜合入賬時視作出售	(75,166)	-
Exchange realignment	匯兌調整	(3,570)	2,357
At the end of the period/year	於期末/年末	-	88,073

NOTES TO INTERIM CONDENSED CONSOLIDATED FINANCIAL INFORMATION

中期簡明綜合財務資料附註

For the six months ended 30 June 2022 截至二零二二年六月三十日止六個月

21. FAIR VALUE AND FAIR VALUE HIERARCHY OF FINANCIAL INSTRUMENTS – continued FAIR VALUE HIERARCHY – continued

21. 金融工具之公平值及公平值層級－續 公平值層級－續

		30 June 2022 二零二二年 六月 三十日 HK\$'000 千港元 (Unaudited) (未經審核)	31 December 2021 二零二一年 十二月 三十一日 HK\$'000 千港元 (Audited) (經審核)
Financial assets at fair value through profit or loss:	透過損益以公平值列賬之金融資產：		
At 1 January	於一月一日	22,607	19,744
Total (losses)/gains recognised in profit or loss	於損益確認之總(虧損)/收益	(4,528)	2,239
Exchange realignment	匯兌調整	(847)	624
At the end of the period/year	於期末/年末	17,232	22,607

During the period, there were no transfers between Level 1 and Level 2 and no transfers into or out of Level 3 for both financial assets and financial liabilities (six months ended 30 June 2021: Nil).

期內，第一級與第二級金融資產及金融負債之間概無轉移，且概無從第三級轉入或轉出之金融資產及金融負債(截至二零二一年六月三十日止六個月：無)。

NOTES TO INTERIM CONDENSED CONSOLIDATED FINANCIAL INFORMATION

中期簡明綜合財務資料附註

For the six months ended 30 June 2022 截至二零二二年六月三十日止六個月

21. FAIR VALUE AND FAIR VALUE HIERARCHY OF FINANCIAL INSTRUMENTS – continued

FAIR VALUE HIERARCHY – continued

Liabilities for which fair values are disclosed

As at 30 June 2022

21. 金融工具之公平值及公平值層級－續

公平值層級－續

披露公平值之負債

於二零二二年六月三十日

Fair value measurement using
使用以下輸入值以公平值計量

	Quoted prices in active markets (Level 1) 活躍市場報價 (第一級) HK\$'000 千港元 (Unaudited) (未經審核)	Significant observable inputs (Level 2) 重大可觀察輸入值 (第二級) HK\$'000 千港元 (Unaudited) (未經審核)	Significant unobservable inputs (Level 3) 重大不可觀察輸入值 (第三級) HK\$'000 千港元 (Unaudited) (未經審核)	Total 總計 HK\$'000 千港元 (Unaudited) (未經審核)
Interest-bearing bank borrowings 計息銀行借款	-	36,905	-	36,905

As at 31 December 2021

於二零二一年十二月三十一日

Fair value measurement using
使用以下輸入值以公平值計量

	Quoted prices in active markets (Level 1) 活躍市場報價 (第一級) HK\$'000 千港元 (Audited) (經審核)	Significant observable inputs (Level 2) 重大可觀察輸入值 (第二級) HK\$'000 千港元 (Audited) (經審核)	Significant unobservable inputs (Level 3) 重大不可觀察輸入值 (第三級) HK\$'000 千港元 (Audited) (經審核)	Total 總計 HK\$'000 千港元 (Audited) (經審核)
Interest-bearing bank borrowings 計息銀行借款	-	36,693	-	36,693

NOTES TO INTERIM CONDENSED CONSOLIDATED FINANCIAL INFORMATION

中期簡明綜合財務資料附註

For the six months ended 30 June 2022 截至二零二二年六月三十日止六個月

22. EVENTS AFTER THE REPORTING PERIOD

On 18 August 2022, the Group subscribed wealth management product amounted to RMB63,000,000 (equivalent to approximately HK\$73,080,000) issued by Bank of Beijing. The wealth management product is non-principal guaranteed with variable return with no fixed maturity period.

23. COMPARATIVE AMOUNTS

Certain comparative amounts have been reclassified to conform to current period's presentation.

24. APPROVAL OF THE INTERIM FINANCIAL INFORMATION

This interim condensed consolidated financial information was approved and authorised for issue by the board of directors on 30 August 2022.

22. 報告期後事項

於二零二二年八月十八日，本集團認購由北京銀行所發行的理財產品人民幣63,000,000元（相當於約73,080,000港元）。理財產品為非本金保證，回報可變，並無固定期限。

23. 比較金額

若干比較金額已重新分類，以符合本期間的呈列方式。

24. 中期財務資料之批准

此中期簡明綜合財務資料已於二零二二年八月三十日獲董事會批准及授權刊發。

MANAGEMENT DISCUSSION AND ANALYSIS

管理層討論及分析

BUSINESS REVIEW

GERIATRIC CARE BUSINESS

Riding on the trend of ageing population in the Chinese society and the rigid market demand, the Group adheres to the strategy of focusing on integrated medical and geriatric care, utilizing medical measures to assist the development of geriatric care and utilizing geriatric care to facilitate medical development, with an aim to develop geriatric care institutions that are professional, chain managed and with temperature. During the period, China promulgated the Plan for the Development of China's Old-age Programs and the Elderly-care Service System during the 14th Five-year Plan Period, which clearly put forward the requirements for vigorously developing the silver-haired economy and promoting the healthy and sustainable development of the silver-haired economy by establishing a systematic and comprehensive industrial development policy.

The Group strived to overcome the adverse impact of the pandemic and adopted various measures to maintain stable operation of bed space of geriatric care institutions and increase occupancy rate of various projects. As of 30 June 2022, the Group operated and managed five geriatric care institutions with a total of 1,055 beds (mainly in the Yangtze River Delta region), including a total of 734 beds for medical care services in three medical institutions. The average occupancy rate reached over 80 and operating cash flow was stable. During the period, revenue from beds of geriatric care institutions reached RMB18.68 million[^] (the first half of 2021: RMB15.85 million), representing a year-on-year increase of 17.8%.

[^] This revenue included the revenue from the private non-enterprise units which were sponsored by the Group's subsidiaries.

業務回顧

養老業務

本集團緊抓中國老齡化社會趨勢和市場剛性需求，堅持走醫養結合道路，以醫助養、以養興醫，致力於打造專業化、連鎖化、有溫度的養老機構。本期間，國家發佈《「十四五」國家老齡事業發展和養老服務體系規劃》，該規劃明確提出大力發展銀髮經濟的要求，通過建立系統性、整體性的產業發展政策推動銀髮經濟健康可持續發展。

本集團努力克服疫情的不利影響，通過各種舉措，維持養老機構床位運營穩定，提升各項目入住率。截至二零二二年六月三十日，本集團經營及管理五家養老機構共提供1,055張床位（主要在長三角地區），其中包括三家醫療機構合共提供734張醫療床位。平均入住率達到80%以上，經營現金流穩定。本期間養老機構床位實現收入人民幣1,868萬元[^]（二零二一年上半年：人民幣1,585萬元），同比增長17.8%。

[^] 此收入包括本集團附屬公司發起之民辦非企業單位之收入。

MANAGEMENT DISCUSSION AND ANALYSIS

管理層討論及分析

Brief Description of Geriatric Care Project

1. Wuxi Liangxi District Guangyi Geriatric Care Center* and Fuma Nursing Home*

First established in July 1983, the residential institution is included in Projects Benefiting the People in 2009 and the total investment made by the local government for reconstruction amounted to over RMB40 million. The residential institution has a built-up area of about 20 acres and total gross floor area of more than 10,000 sq.m.. The residential institution has double qualification of geriatric care center and nursing home. It was honored with provincial and municipal demonstrative geriatric care institutions and advanced unit consecutively for many years.

- Opening date: 2015
- Number of beds: 285, of which 214 beds are for medical care service
- Occupancy rate: 95%

2. Wuxi Liangxi District Wuhe Geriatric Care Center* and Yikang Nursing Home*

Established in 2012, the project is situated at Block C, 20 Antou Qiao, Wuxi. It has a gross floor area of approximately 3,500 sq.m. and has double qualification of geriatric care center and nursing home. The center has set up function rooms such as chess room, reading room, studio, rehabilitation room.

- Opening date: December 2018
- Number of beds: 160, of which 120 beds are for medical care service
- Occupancy rate: 90%

養老項目簡介

1. 無錫市梁溪區廣益養老中心及福媽護理院

本院始建於一九八三年七月，二零零九年被列入惠民工程由地方政府進行投資重建，總投資達人民幣4,000多萬元。院舍佔地面積約20畝，總建築面積1萬餘平方米。院舍擁有養老院護理院雙資質。連續多年榮獲省、市示範性養老機構、先進單位等。

- 開業時間：二零一五年
- 床位數：285張，其中醫療床位214張
- 入住率：95%

2. 無錫市梁溪區五河養老院及依康護理院

本院創辦於二零一二年，項目位於無錫庵頭橋20號C幢，建築面積約3,500平方米，擁有養老院及護理院雙資質。院舍內設棋牌室、閱覽室、書畫室、康復房等功能房。

- 開業時間：二零一八年十二月
- 床位數：160張，其中醫療床位120張
- 入住率：90%

MANAGEMENT DISCUSSION AND ANALYSIS

管理層討論及分析

3. *Changzhou Xinbei District Xuejia Aixin Nursing Home**

The institution is situated at the centre of Xuejiazhen, Xinbei District, Changzhou with a gross floor area of approximately 12,500 sq.m.. It has a green area of approximately 6,200 sq.m.. There are two buildings, the southern block has 3 floors and the northern block has 4 floors. The residential institution has double qualification of geriatric care center and nursing home.

- Opening date: June 2020
- Number of beds: 400, of which 400 beds are for medical care service
- Occupancy rate: 40%

4. *Wuxi Liangxi District Hui Feng Yikangyuan**

The institution was built in April 2005. The Group took over in 2017 and carried out renovation and alteration. The gross floor area was 2,400 sq.m.. Green coverage reached 60%. The residential institution has set up function rooms such as chess room, reading room, studio and gym room. The outdoor garden provides sufficient space for the elders.

- Opening date: December 2017
- Number of beds: 100
- Occupancy rate: 50%

3. *常州市新北區薛家愛心護理院*

本院位於常州市新北區薛家鎮中心位置，建築面積約12,500平方米，綠化面積約6,200平方米，分為南北兩棟，南樓共三層，北樓共四層。院舍擁有養老院及護理院雙資質。

- 開業時間：二零二零年六月
- 床位數：400張，其中醫療床位400張
- 入住率：40%

4. *無錫市梁溪區惠楓怡康院*

本院建於二零零五年四月，二零一七年本集團接管營運並進行裝修改建，建築面積2,400平方米，綠化覆蓋率達60%。院舍內設棋牌室、閱覽室、書畫室、健身房等功能房，室外花園為長者提供充足活動空間。

- 開業時間：二零一七年十二月
- 床位數：100張
- 入住率：50%

MANAGEMENT DISCUSSION AND ANALYSIS

管理層討論及分析

5. Wuhu Jinghu District Elderly Care Centre*

The institution is situated at 3-1 land parcel, Century City, Jinghu District, Wuhu city. It was converted from Jinghu District Old-age University with a gross area of 3,300 sq.m.. The residential institution provides services such as long term and short term foster care, day care and respite care. Meanwhile, it provides home health care social services to the nearby areas.

- Opening date: August 2018
- Number of beds: 110
- Occupancy rate: 90%

5. 蕪湖市鏡湖區長者照護中心

本院位於蕪湖市鏡湖區世紀城3-1地塊，由鏡湖區老年大學改建而成。建築面積3,300平方米。院舍提供長短期托養、日間照料、喘息照料等服務，同時輻射周邊提供居家社區服務。

- 開業時間：二零一八年八月
- 床位數：110張
- 入住率：90%

HEALTH INDUSTRIAL PARK BUSINESS

The Group acquired land parcels of high-quality mainly in first-tier cities such as Beijing and Shanghai based on the policies and directions on land planning adjustments of central and local governments. Leveraging on the transformation and upgrading, the Group introduced advanced industrial construction philosophy to fully satisfy the needs of the government and market users with the focus being placed on new modes of business operations such as setting up corporate headquarters and healthcare industrial parks.

As of 30 June 2022, the Group participated in six projects in total in Beijing, Shanghai, Dali and Canada with a total site area of over 400,000 sq.m.. The implementation plans of each of the projects have gained support from the local governments where the projects are located. As the projects are positioned in line with the market demand, it is expected that the projects will have considerable potential for appreciation in commercial value.

健康產業園業務

本集團根據國家和各地方政府對土地規劃調整的政策和方向，主要在北京、上海等一線城市獲取優質土地，通過轉型升級，引入先進的產業建設理念，全面滿足政府、市場用戶的需求，重點建設企業總部及健康產業園等新型業態。

截至二零二二年六月三十日止，本集團在北京、上海、大理及加拿大共參與六個項目，總佔地超過40萬平方米，各項目實施方案已取得項目所在地之政府支持，項目定位符合市場需求，商業價值提升潛力巨大。

MANAGEMENT DISCUSSION AND ANALYSIS

管理層討論及分析

As of 30 June 2022, the progress of the Group's projects under development as follows:

截至二零二二年六月三十日，本集團之開發項目進展如下：

Location 地點	Project Name 項目名稱	Land Area 土地面積 (m ²) (平方米)	Shareholding	Future Planning of the Project 項目未來規劃	Project Status 項目進展
			Percentage 股權佔比		
Beijing 北京	Chaoyang Port Project 朝陽口岸項目	87,607	82.24%	Through actively pushing forward government approval procedure and completing the preparation work before construction, the Group facilitated the inclusion of Chaoyang Port Project, which is positioned as the intelligent cold chain distribution center in Chaoyang Port of Beijing, into the key projects of Beijing and reserved quality partners with an aim to develop a benchmark demonstration project for intelligent cold chain in Beijing 定位「北京朝陽口岸智慧冷鏈配送中心」，納入北京市重點項目，儲備優質合作方，積極推進政府審批手續，做好開工前準備工作，打造北京市智慧冷鏈標桿示範項目	The preparation of relevant documents such as "Report on Project Planning and Operation Proposal" and the inclusion of relevant documents such as "Combination of Multiple Rules into One" was completed. The report has been accepted by the Chaoyang District Commission of Planning and Natural Resources for approval. The Group is actively seeking local demolition targets and will apply to the government for construction targets and proceed with the development of the project once the demolition targets are obtained. Quality partners have been reserved for this project, which include investors, operators and tenants. 已為本項目儲備優質合作方，其中包括：投資方、運營方及租賃方。

MANAGEMENT DISCUSSION AND ANALYSIS

管理層討論及分析

Location 地點	Project Name 項目名稱	Land Area 土地面積 (m ²) (平方米)	Shareholding		Project Status 項目進展
			Percentage 股權佔比	Future Planning of the Project 項目未來規劃	
Shanghai 上海	Sanlu Road Project 三魯路項目	20,480	20%	This project has been completed as a new industrial park and is recruiting tenants 本項目已建成為新型產業園並對外招租運營中	Properties are recruiting tenants. 物業招租運營中。
Shanghai 上海	Hongmei Road Project 虹梅路項目	39,448	100%	This project is strategically located in the core area of Shanghai. The Group intends to bring in quality partners to jointly develop this project as a landmark for leasing projects in the region 本項目位於上海核心區域，地理位置優越，本集團擬引入優質合作方共同開發本項目為當區租賃項目地標	The Group initiated the adjustment of project positioning and design plan during the period in accordance with the changes in market and policies. 本集團根據市場及政策的變化，本期間開啟調整項目定位及設計方案的工作。 Quality partners have been reserved. 完成優質合作方的儲備。
Dali 大理	Haidong New District Project 海東新區項目	275,181	60%	Greater health industrial park complex including lands for residential, commercial and medical purposes 大健康產業園綜合體，包括住宅、商業及醫衛用地	As the Yunnan provincial government suspended its approval process for the development and construction in Haidong New District, this project is temporarily withheld. 由於雲南省政府暫停審批海東新區開發建設，本項目暫時停止狀態。 The Group is discussing with the local government on the follow-up arrangements. 本集團正與當地政府商討後續安排。

MANAGEMENT DISCUSSION AND ANALYSIS

管理層討論及分析

Location 地點	Project Name 項目名稱	Land Area 土地面積 (m ²) (平方米)	Shareholding		Project Status 項目進展
			Percentage 股權佔比	Future Planning of the Project 項目未來規劃	
Canada 加拿大	Ovation	2,425	N/A ⁽¹⁾ 不適用 ⁽¹⁾	Artistic health apartments 藝術健康公寓	The pre-sale of this project began in April 2019, and approximately 70% of the saleable area were sold currently. 本項目自二零一九年四月起預售，目前已售出可售面積約70%。
Canada 加拿大	Royal Tower	10,588	47.47%	Urban health apartments 都市健康公寓	We are preparing the application of replanning the nature of project land development, and seeking appropriate partners. 正在籌備項目土地發展性質重新規劃手續，並尋找合適之合作方。

Note⁽¹⁾: This project is engaged in the form of debt investment. 註⁽¹⁾: 本項目以債權投資方式參與。

SALE OF MEDICAL AND GERIATRIC PRODUCT

Beijing Vissam Prosperity Furniture Limited* (北京偉森盛業傢俱有限公司) ("Vissam Prosperity"), a company under the Group engaging in medical and geriatric product business, continued to penetrate into the specialized furniture industry in areas such as geriatric care, medical and education. On the basis of fulfilling the requirements for professional, green and environmentally friendly products, we continued to maintain a leading position in the industry with "meeting people's healthcare needs" as the core value of our products.

醫養產品銷售

本集團下屬的醫養產品公司北京偉森盛業傢俱有限公司(「偉森盛業」)繼續深耕養老、醫療、教育專業傢俱行業，在滿足專業、綠色、環保的要求基礎上，以「人的健康需求」為產品核心，繼續保持行業領先。

MANAGEMENT DISCUSSION AND ANALYSIS

管理層討論及分析

Affected by the pandemic in the first half of 2022, the market development and business growth encountered unprecedented resistance. The achievement of the performance and acceptance in the first half of the year is the result of the company's long-term accumulation and precipitation of customers, as well as the joint efforts of all employees. Overcoming the impact of the pandemic on the market development, Vissam Prosperity entered into contracts with various projects such as Chongqing Oncology Hospital, Suzhou Huixin Jia'an Clinic, South China University of Technology, Guangzhou Peiwen Foreign Language School, Hainan Weicheng Future School, Shanghai Lingke College, Shanghai Zhuqiao Experimental Primary School and Chengdu Anju World. As of 30 June 2022, Vissam Prosperity has signed but undelivered contracts of approximately RMB68.67 million, and the recognized revenue was approximately RMB72.92 million.

Vissam Prosperity continued to improve the technological content of the enterprise and industry professional standards. In the first half of 2022, it obtained 3 patents and 4 product safety certificates, and participated in the group standard of "General Technical Requirements for Geriatric Care Related Furniture" jointly compiled by China Building Materials Market Association and Beijing Furniture Industry Association, which was officially implemented in May 2022. It participated in the national standard GB24820-2009 "General Technical Requirements for Laboratory Furniture" which was under compilation and revision.

二零二二年上半年受疫情影響，市場開拓和業績增長遇到前所未有的阻力，上半年業績和驗收的達成是公司長久以來對客戶的積累及沉澱，以及所有員工全力以赴共同達成的結果。偉森盛業克服疫情對市場開拓的影響，成功簽約了重慶腫瘤專科醫院、蘇州慧心嘉安門診、華南理工大學、廣州培文外國語學校、海南微城未來學校、上海領科專修學院、上海築橋實驗小學、成都安居天下等項目，截至二零二二年六月三十日止，偉森盛業已簽定但尚未交付之合同金額約人民幣6,867萬元，確認收入金額約人民幣7,292萬元。

偉森盛業繼續提升企業科技含量和行業專業化標準，於二零二二年上半年獲得3項專利、4款產品安全認證證書，參與中國建材市場協會和北京傢俱行業協會共同編製的《適老傢俱通用技術要求》團體標準於二零二二年五月正式實施，參加的國家標準GB24820-2009《實驗室傢俱通用技術條件》正在參與編製修訂中。

MANAGEMENT DISCUSSION AND ANALYSIS

管理層討論及分析

FUTURE PROSPECT

Heading into the second half of 2022, the Group's business is inevitably subject to many challenges. However, the Group is optimistic on and remain confident in Chinese geriatric market and its peripheral businesses (e.g. geriatric care related furniture and geriatric care related real estate).

In respect of the geriatric industry, the Chinese government has issued a series of policies and measures to support the development of the geriatric care and health industry, clearly proposing to implement a national strategy to actively respond to the aging of the population, improve the geriatric service system, strengthen planning and guidance, and actively cultivate the silver-haired economy. Therefore, the Group is actively discussing with a number of insurance companies on cooperation opportunities in the field of geriatric care, seeking a differentiated deployment model and hoping to jointly develop new products and services of "Geriatric Care + Insurance".

未來展望

踏入二零二二年下半年，本集團的業務無可避免面臨多重挑戰，然而，本集團依然對中國養老市場及相關周邊業務（其中包括養老傢俱、養老地產等）充滿信心，並秉持正面樂觀的態度。

在養老產業方面，中國政府出台一系列支持養老健康產業發展的政策措施，明確提出實施積極應對人口老龄化的國家戰略，完善養老服務體系，加強規劃引導，積極培育銀髮經濟。因此，本集團正積極與多間保險公司在養老領域商談合作機遇，尋求差異化佈局模式，期望能共同發展出「養老+保險」的新型產品及服務。

MANAGEMENT DISCUSSION AND ANALYSIS

管理層討論及分析

In respect of health industrial park, since the strengthening of the regulation of the real estate industry in China in 2021, the domestic real estate industry has been under tremendous pressure of highly indebted. Fortunately, the Group has always maintained a stable development policy with a low debt ratio and has not been greatly impacted by this industry wave. However, as this is an asset-heavy business, the Group will not increase its deployment on health industrial park for the time being as the macro-environment was unclear and the control on Chinese real estate enterprises was tightened. Through actively pushing forward government approval procedure and completing the preparation work before construction, the Group is expected to facilitate the positioning of Chaoyang Port of Beijing as the intelligent cold chain distribution center in the second half of the year, with an aim to develop a benchmark demonstration project for intelligent cold chain in Beijing.

In respect of medical and geriatric product business, although the erratic nature of the pandemic has made market development more difficult, the Group expects that there will be no large-scale epidemic prevention and control enclosed management in China and the Group's medical and geriatric product business will gradually return to normal with sales and profit growth. At the same time, the Group is actively identifying suitable merger and acquisition targets to increase the investment and development of this business in the hope of generating greater returns for shareholders.

In respect of the Group's overall strategy, we will exercise stringent cost control and optimize cost efficiency by putting resources to good use. We will manage our own capital prudently and enhance our financial position by increasing income through appropriate investments in wealth management products, equity and bonds.

在健康產業園方面，自二零二一年國家對地產行業加強監管起，國內地產行業面對高負債的巨大壓力一直未能減輕，尤幸本集團一向秉承低負債率的穩健發展方針，沒有受到本次行業巨浪太大的衝擊。但由於本業務為重資產業務，在宏觀環境不明朗及國內對房地產企業調控加強的情況下，本集團暫不會加大於健康產業園的投入。預計下半年，本集團將積極推進定位智慧冷鏈配送中心的「北京朝陽口岸」項目的政府審批手續，做好開工前準備工作，打造北京市智慧冷鏈的標桿示範項目。

在醫養產品業務方面，雖然疫情反覆無常，加深市場開拓之困難，但本集團預計國內將不會進行大規模的抗疫封閉管理，本集團之醫養產品銷售業務將逐漸回復正常，銷售及盈利保持增長。與此同時，本集團正積極物色合適的併購標的公司，加大本業務之投入及發展，期望為股東創造更大之收益。

在集團整體策略方面，我們將嚴謹管控成本，讓資源用得其所，優化成本效益。審慎管理自有資金，通過適量的銀行理財、股票及債券投資提高收益，加強本集團的財務狀況。

MANAGEMENT DISCUSSION AND ANALYSIS

管理層討論及分析

FINANCIAL REVIEW

OPERATING REVENUE

For the first half of 2022, the operating revenue of the Group was HK\$91,807,000, representing an increase of 15.3% as compared to the corresponding period last year, which was mainly due to the gradual recovery of sales of medical and geriatric products to pre-pandemic level. The related revenue during the period increased by 16.5% to HK\$88,126,000.

COST OF SALES

Cost of sales was HK\$66,553,000, representing a year-on-year increase of 16.6%. Cost of sales mainly includes cost of purchases, freight, installation fees and wage expenses.

GROSS PROFIT MARGIN

During the period, the overall gross profit margin of the Group was 27.5%, representing a slight decrease of 0.8% as compared to 28.3% for the corresponding period last year, which was however still lower than that of 35% in usual years. It was mainly due to the fact that the COVID-19 outbreak has not yet ended. In order to maintain sales volume, the Group continued to adopt the sales strategy of “small profits but quick turnover” and signed some contracts with lower gross profit.

OTHER INCOME AND GAINS, NET

For the first half of 2022, other income and gains, net was approximately HK\$22,851,000, representing a decrease of 44.9% as compared to HK\$41,456,000 for the corresponding period last year. The decrease in other income and gains, net was mainly due to the one-off reversal of impairment loss on investment in an associate of HK\$13,527,000 and gain on foreign exchange difference of HK\$8,576,000 for the first half of 2021 while no such gains were incurred in the first half of 2022.

財務回顧

營業收入

二零二二年上半年，本集團之營業收入為91,807,000港元，較去年同期增加15.3%，主要是由於醫養產品銷售逐步回復至疫情前水平，本期間相關收入增加16.5%至88,126,000港元。

銷售成本

銷售成本同比上升16.6%至66,553,000港元。銷售成本主要包括採購成本、運費、安裝費及工資費用等。

毛利率

本期間，本集團整體毛利率為27.5%，而去年同期則為28.3%，輕微下降0.8%，但仍較往年年度35%毛利率水準為低，主要由於新冠病毒疫情尚未完結，為保持銷售量，本集團繼續以「薄利多銷」的銷售策略，簽訂一些毛利較低的合同所致。

其他收入及收益淨額

二零二二年上半年，其他收入及收益淨額約為22,851,000港元，比去年同期41,456,000港元減少44.9%。其他收入及收益淨額減少主要由於二零二一年上半年產生一次性撥回於一間聯營公司之投資的減值虧損13,527,000港元及錄得匯兌差額收益8,576,000港元而二零二二年上半年並沒產生相關收益所致。

MANAGEMENT DISCUSSION AND ANALYSIS

管理層討論及分析

Excluding the reversal of impairment loss on investment in an associate and gain on foreign exchange difference, other income and gains, net mainly included bank interest, other interest, dividend and investment income of HK\$12,310,000 (corresponding period in 2021: HK\$17,952,000), rental income of HK\$6,575,000 (corresponding period in 2021: HK\$4,593,000), gains in disposal of equity investments designated at fair value through other comprehensive income of HK\$1,410,000 (corresponding period in 2021: nil) and gains in redemption of a debt investment at fair value through other comprehensive income of HK\$4,375,000 (corresponding period in 2021: nil).

SELLING AND DISTRIBUTION EXPENSES

For the first half of 2022, the selling and distribution expenses were HK\$6,429,000 (corresponding period in 2021: HK\$5,691,000), representing 7.0% of the total sales amount (corresponding period in 2021: 7.1%). Selling and distribution expenses mainly included salaries of approximately HK\$2,874,000 (corresponding period in 2021: HK\$3,590,000) and promotional fees of approximately HK\$787,000 (corresponding period in 2021: HK\$491,000).

The increase in the selling and distribution expenses during the period was attributable to the increase in sales of the Group in the first half of 2022, which as a percentage of total sales was basically the same as the corresponding period last year.

除去撥回於一間聯營公司之投資的減值虧損及匯兌差額收益外，其他收入及收益淨額主要為銀行利息、其他利息、股息及投資收入12,310,000港元(二零二一年同期：17,952,000港元)、租金收入6,575,000港元(二零二一年同期：4,593,000港元)、處置指定為透過其他全面收益以公平值列賬之權益投資收益1,410,000港元(二零二一年同期：無)及贖回按公平值計入其他全面收益的債權投資收益4,375,000港元(二零二一年同期：無)。

銷售及分銷開支

二零二二年上半年之銷售及分銷開支為6,429,000港元(二零二一年同期：5,691,000港元)，佔總銷售金額7.0%(二零二一年同期：7.1%)。銷售及分銷開支主要包括薪酬約2,874,000港元(二零二一年同期：3,590,000港元)及推廣費用約787,000港元(二零二一年同期：491,000港元)。

本期間銷售及分銷開支增加要由於本集團之二零二二年上半年之銷售增加所致，佔總銷售比率基本與去年同期持平。

MANAGEMENT DISCUSSION AND ANALYSIS

管理層討論及分析

ADMINISTRATIVE EXPENSES

For the first half of 2022, the administrative expenses were HK\$55,951,000, representing a decrease of 11.6% in expenses as compared to HK\$63,293,000 for the corresponding period last year. The administrative expenses mainly included staff costs (including directors' remuneration) of HK\$22,714,000 (corresponding period in 2021: HK\$23,205,000), professional advisory fees of HK\$4,508,000 (corresponding period in 2021: HK\$4,843,000), depreciation charge of HK\$14,350,000 (corresponding period in 2021: HK\$16,153,000), business entertainment expenses of HK\$1,409,000 (corresponding period in 2021: HK\$1,586,000), travelling expenses of HK\$981,000 (corresponding period in 2021: HK\$1,470,000) and office costs of HK\$4,044,000 (corresponding period in 2021: HK\$5,908,000). The decrease in administrative expenses was mainly due to the decrease in depreciation expenses as a result of the Group's office in Beijing, which was leased out in the second half of 2021 and reclassified to investment properties, and one-off maintenance expenses of HK\$4,282,000 incurred in 2021 while no such expenses were incurred in the first half of 2022.

IMPAIRMENT LOSSES OF FINANCIAL ASSETS

Impairment losses of financial assets were mainly attributable to the provision for impairment of the Group's receivables, other receivables and debt investments. During the period, some other receivables were not repaid on time due to the continued impact of the pandemic. Taking into account the repayment ability of the defaulters, the Group has made a provision for impairment of the affected balances.

行政開支

二零二二年上半年之行政開支為55,951,000港元，較去年同期63,293,000港元的開支減少11.6%。行政開支主要包括員工成本（包括董事薪酬）22,714,000港元（二零二一年同期：23,205,000港元）、專業諮詢費4,508,000港元（二零二一年同期：4,843,000港元）、折舊費用14,350,000港元（二零二一年同期：16,153,000港元）、業務招待費1,409,000港元（二零二一年同期：1,586,000港元）、差旅費981,000港元（二零二一年同期：1,470,000港元）及辦公費用4,044,000港元（二零二一年同期：5,908,000港元）等。行政開支減少主要是由於本集團位於北京的辦公室於二零二一年下半年出租並重新分類到投資物業引致折舊費用減少，以及二零二一年產生一次性維修工程費用4,282,000港元而二零二二年上半年並沒產生相關費用所致。

金融資產減值虧損

金融資產減值虧損主要為對本集團之應收賬款、其他應收賬款及債券投資所作之減值撥備。本期間由於依然受到疫情之影響，部份其他應收款未能按期償還。經考慮到欠款人之還款能力，本集團已對受影響之餘額作出減值撥備。

MANAGEMENT DISCUSSION AND ANALYSIS

管理層討論及分析

OTHER EXPENSES AND LOSSES

Other expenses and losses were mainly one-off non-cash charges. For the six months ended 30 June 2022, the Group incurred other expenses and losses of HK\$1,806,000, representing a decrease of 66.3% from HK\$5,356,000 for the corresponding period last year. A loss on disposal of equity interest in associates of HK\$5,291,000 was incurred for the corresponding period in 2021, while a profit on disposal of equity interest in an associate of HK\$858,000 was incurred and recorded in other income and gains, net in 2022. Other expenses and losses for the first half of 2022 mainly included exchange losses of HK\$1,670,000 (corresponding period in 2021: exchange gains of HK\$8,576,000 recorded in other income and gains, net).

FINANCE COSTS

For the first half of 2022, the total finance costs were HK\$602,000 (corresponding period in 2021: HK\$949,000), representing a decrease of 36.6% as compared with that in the corresponding period last year, which was mainly due to the drop in the weighted average balance of borrowings of the Group during the period.

SHARE OF PROFITS AND LOSSES OF JOINT VENTURES

Share of profits and losses of joint ventures mainly included the share of 47.47% of loss attributable to shareholders of 1121695 B.C. Ltd. of approximately HK\$6,249,000 (corresponding period in 2021: HK\$1,083,000).

其他開支及虧損

其他開支及虧損主要為一次性非現金支出的費用，截至二零二二年六月三十日六個月止，本集團之其他開支及虧損為1,806,000港元，比去年同期5,356,000港元減少66.3%。二零二一年同期產生處置聯營公司股權虧損5,291,000港元，而二零二二年則產生處置一間聯營公司股權利潤858,000港元並列賬於其他收入及收益淨額。二零二二年上半年其他開支及虧損主要為外匯差異虧損1,670,000港元（二零二一年同期：列賬於其他收入及收益淨額內的外匯差異收益8,576,000港元）。

融資成本

二零二二年上半年之總融資成本為602,000港元（二零二一年同期：949,000港元），較去年同期減少36.6%，主要是由於本期間本集團的加權平均借貸餘額下跌所致。

應佔合營公司溢利及虧損

應佔合營公司盈虧主要為應佔1121695 B.C. Ltd.股東應佔虧損之47.47%約6,249,000港元（二零二一年同期：1,083,000港元）。

MANAGEMENT DISCUSSION AND ANALYSIS

管理層討論及分析

SHARE OF PROFITS AND LOSSES OF ASSOCIATES

Share of profits and losses of associates mainly included the share of 25.07% of loss attributable to shareholders of Beijing Sports and Entertainment Industry Group Limited of approximately HK\$4,346,000 (corresponding period in 2021: HK\$363,000), and the share of 20% of loss attributable to shareholders of Shanghai Junbo Textiles Limited* of approximately HK\$3,390,000 (corresponding period in 2021: HK\$2,253,000).

NET ASSETS

As at 30 June 2022, the net assets of the Group was approximately HK\$2,295,443,000, representing a decrease of approximately HK\$201,176,000 from approximately 2,496,619,000 as at 31 December 2021. Excluding the generation of loss of approximately HK\$34,387,000 during the period, the net assets decreased by HK\$166,789,000 as compared to 31 December 2021, which was mainly due to the depreciated exchange rate of RMB against Hong Kong dollar of approximately 4.4% during the first half of 2022, the Group recognized exchange losses of HK\$75,802,000 in other comprehensive income and losses as well as the decrease in non-controlling interest of HK\$71,156,000 as a result of the deconsolidation of a subsidiary.

LIQUIDITY AND FINANCIAL RESOURCES

As at 30 June 2022, the Group held cash and cash equivalents of approximately HK\$137,928,000 (31 December 2021: HK\$239,136,000) and had restricted bank balances of approximately HK\$4,120,000 (31 December 2021: HK\$3,994,000).

As at 30 June 2022, interest-bearing bank borrowings of the Group amounted to approximately HK\$36,905,000 (31 December 2021: HK\$36,693,000).

應佔聯營公司溢利及虧損

應佔聯營公司盈虧主要包括應佔北京體育文化產業集團有限公司之股東應佔虧損之25.07%約4,346,000港元(二零二一年同期: 363,000港元)及應佔上海駿帛紡織品有限公司之股東應佔虧損之20%約3,390,000港元(二零二一年同期: 2,253,000港元)。

資產淨值

於二零二二年六月三十日, 本集團資產淨值約為2,295,443,000港元, 較二零二一年十二月三十一日約2,496,619,000港元減少約201,176,000港元。除本期間產生虧損約34,387,000港元, 資產淨值較二零二一年十二月三十一日減少166,789,000港元, 主要因為人民幣兌港元匯率於二零二年上半年貶值約4.4%, 集團於其他全面收益虧損確認匯兌虧損75,802,000港元; 及因一間附屬公司不再綜合入賬導致非控股權益減少71,156,000港元所致。

流動資金及財務資源

於二零二二年六月三十日, 本集團持有之現金及現金等值物約137,928,000港元(二零二一年十二月三十一日: 239,136,000港元), 約4,120,000港元受限制銀行結餘(二零二一年十二月三十一日: 3,994,000港元)。

於二零二二年六月三十日, 本集團之計息銀行借貸約36,905,000港元(二零二一年十二月三十一日: 36,693,000港元)。

MANAGEMENT DISCUSSION AND ANALYSIS

管理層討論及分析

As at 30 June 2022, the net current assets of the Group amounted to HK\$470,146,000 and the current ratio was 3.2 times. The Group maintained sufficient bank credit facilities to meet working capital needs and had sufficient cash resources to finance its capital expenditure in the foreseeable future.

The Group agreed that meticulous management on cash flow is the key to success. To ensure that there is sufficient capital to satisfy the need of the Group's rapid growth, the Group remains good relationships with each of the banks from time to time, so that the Group gains easy access to application for loans.

CAPITAL STRUCTURE

The Group took full advantage of the financing platform as a listed company by striving for a constant optimisation of the capital and financing structure, so as to obtain sufficient funds to finance the future projects of health and geriatric care. During the period, the Group's operations were mainly financed by internal resources and bank loans.

As at 30 June 2022, the number of issued share of the Company was 6,078,944,027 shares. Equity attributable to shareholders of the Company amounted to approximately HK\$2,181,038,000 (31 December 2021: approximately HK\$2,293,624,000) and total equity was approximately HK\$2,295,443,000 (31 December 2021: approximately HK\$2,496,619,000). The gearing ratio (i.e. bank borrowings divided by total assets) remained at a low level of 1.4% (31 December 2020: 1.2%).

於二零二二年六月三十日，本集團淨流動資產達470,146,000港元，流動比率為3.2倍。本集團保持足夠銀行信貸融資以滿足營運資金需要，並持有充裕現金資源於可見未來撥付資本開支。

本集團認為審慎之現金流管理乃成功之關鍵。為確保資金足以應付本集團之快速增長，本集團不時與各銀行保持良好業務關係，以便本集團日後易於提出借貸申請。

資本結構

本集團充分利用作為上市公司的融資平台優勢，力求不斷優化資本及融資結構，以為未來健康及養老產業項目取得充足資金。期內，本集團的業務運作主要透過內部資源及銀行貸款提供資金。

於二零二二年六月三十日，本公司已發行股數為6,078,944,027股股份，本公司股東應佔權益約2,181,038,000港元(二零二一年十二月三十一日：約2,293,624,000港元)，總權益約2,295,443,000港元(二零二一年十二月三十一日：約2,496,619,000港元)。資產負債比(即銀行借款除以總資產)1.4%(二零二零年十二月三十一日：1.2%)維持較低水平。

MANAGEMENT DISCUSSION AND ANALYSIS

管理層討論及分析

CAPITAL EXPENDITURE

For the six months ended 30 June 2022, the Group's capital expenditure was approximately HK\$16,808,000 (corresponding period in 2021: HK\$2,250,000), which was mainly due to the purchase of investment properties and properties, plants and equipment.

資本開支

截至二零二二年六月三十日止六個月期間，本集團資本開支為約16,808,000港元(二零二一年同期：2,250,000港元)，主要為購置投資物業及物業、廠房及設備。

PLEDGE OF ASSETS

As at 30 June 2022, the following assets were pledged to secure the banking facilities granted to the Group:

資產抵押

於二零二二年六月三十日，已抵押以下資產，作為本集團獲授銀行授信之擔保：

		30 June 2022 二零二二年 六月 三十日 HK\$'000 千港元	31 December 2021 二零二一年 十二月 三十一日 HK\$'000 千港元
Property, plant and equipment	物業、廠房及設備	24,348	26,363
Investment properties	投資物業	31,560	32,642
Right-of-use assets	使用權資產	-	383,084
Equity investments designated at fair value through other comprehensive income	指定為透過其他全面收益以公平值列賬之權益投資	29,715	-
Financial assets at fair value through profit or loss	透過損益以公平值列賬之金融資產	3,341	-
Cash and cash equivalents	現金及現金等值物	4,120	-
		93,084	442,089

MANAGEMENT DISCUSSION AND ANALYSIS

管理層討論及分析

MATERIAL INVESTMENTS

On 17 January 2022 and 20 January 2022, the Group purchased the senior unsecured bonds issued by Radiance Capital Investments Limited (the “Bond”) of principal amounts of US\$2,300,000 and US\$2,700,000, respectively, at the total consideration of approximately US\$4,512,000 (equivalent to approximately HK\$35,154,000) in the secondary market, due on 17 September 2023 with the coupon of 8.8% per annum. The Bond was early redeemed on 17 June 2022.

On 24 January 2022, the Group subscribed wealth management product of RMB60,000,000 (equivalent to approximately HK\$72,510,000) issued by Xiamen International Bank Co., Limited. The wealth management product is non-principal guaranteed with variable return and has each holding period represents 182 natural days with no fixed maturity period. The wealth management product was redeemed on 28 July 2022.

Save as disclosed above, the Group had no additional material investment for the period ended 30 June 2022.

The Group is actively identifying and exploring suitable investments with potential and synergy effect to its existing businesses. The Group will only consider any potential investments which are in the interests of the Company and the shareholders as a whole. No agreement for material investment has been entered into as at the date of this report.

重大投資

於二零二二年一月十七日及二零二二年一月二十日，本集團於第二市場上分別購入本金額為2,300,000美元及2,700,000美元，由金輝資本投資有限公司發行，票面息率為年息8.8%並二零二三年九月十七日到期之優先無抵押債券（「該債券」），總代價約4,512,000美元（相當於約35,154,000港元）。該債券已於二零二二年六月十七日提前贖回。

於二零二二年一月二十四日，本集團認購由廈門國際銀行股份有限公司所發行的理財產品人民幣60,000,000元（相當於約72,510,000港元）。該理財產品為非保本浮動收益類型，以182個自然日為一個持有週期，並無固定到期限期。該理財產品已於二零二二年七月二十八日贖回。

除上文所披露者外，截至二零二二年六月三十日止期間，本集團並無新增任何重大投資。

本集團正積極尋找及探索潛在及具有協同效應的合適投資，以將其帶至現行的業務。本集團將只考慮以本公司及股東整體利益為依歸的任何潛在投資。截至本報告日期，並未訂立重大投資的協議。

MANAGEMENT DISCUSSION AND ANALYSIS

管理層討論及分析

CONTINGENT LIABILITIES

The Group has contingent liabilities up to RMB28,000,000 (equivalent to approximately HK\$32,741,000) as a guarantor for the bank facility granted to an associate of the Company (31 December 2021: RMB28,000,000 (equivalent to approximately HK\$34,247,000)).

As at 30 June 2022, the associate has utilized bank loans of approximately RMB26,554,000 (equivalent to approximately HK\$31,050,000) which is guaranteed by the Group (31 December 2021: approximately RMB26,386,000 (equivalent to approximately HK\$32,273,000)).

Save as disclosed above, the Group has no significant contingent liabilities as at 30 June 2022.

FOREIGN EXCHANGE RISK

The Group's exposure to foreign exchange risks primarily arises from other receivables and investment in joint ventures denominated in CAD as well as cash and cash equivalents and equity investments at fair value through other comprehensive income denominated in US dollars. In respect of the Group's exposure to potential foreign exchange risks arising from the currency exchange rate fluctuations, it did not make any arrangement or use any financial instruments to hedge against potential foreign exchange risks. However, the management will continue to monitor foreign exchange risks and adopt hedging measures where necessary.

或然負債

本集團就授予本公司一間聯營公司之銀行融資作為擔保人，擁有或然負債最多人民幣28,000,000元(相當於約32,741,000港元)(二零二一年十二月三十一日：人民幣28,000,000元(相當於約34,247,000港元))。

於二零二二年六月三十日，該聯營公司已動用由本集團提供擔保的銀行貸款約人民幣26,554,000(相當於約31,050,000港元)(二零二一年十二月三十一日：約人民幣26,386,000元(相當於約32,273,000港元))。

除上文披露者外，於二零二二年六月三十日，本集團並無重大或然負債。

外匯風險

本集團所承受的外匯風險主要來自於以加拿大元結算的其他應收款項及對合營公司之投資，以及以美元結算的現金及現金等值物及透過其他全面收益以公平值列賬的權益投資。本集團面對貨幣匯率波動所產生之潛在外匯風險，並無作出任何安排或利用任何財務工具對沖潛在外匯風險，然而，管理層將繼續監察外匯風險，並在需要時採取對沖措施。

MANAGEMENT DISCUSSION AND ANALYSIS

管理層討論及分析

EMPLOYEES AND REMUNERATION POLICY

As at 30 June 2022, the Group had approximately 168 (corresponding period in 2021: 241) employees. Total staff costs (including Directors' emoluments) for the six months ended 30 June 2022 amounted to approximately HK\$26,242,000 (corresponding period in 2021: approximately HK\$27,634,000).

The Group's remuneration policy is that all employees are rewarded on the basis of market levels. In addition to salaries, the Group provides staff benefits including medical insurance, contribution to staff's mandatory provident fund and social insurance in the PRC. To motivate and reward staff, the Group has a discretionary performance bonus scheme and a year-end award scheme to drive their performance and growth. The Company has also established a share option scheme and an employee option scheme to recognize the performance of its employees.

僱員及薪酬政策

於二零二二年六月三十日，本集團有員工約168名(二零二一年同期：241名)，而截至二零二二年六月三十日止六個月期間之總員工成本(包括董事酬金)約26,242,000港元(二零二一年同期：約27,634,000港元)。

本集團的薪酬政策是所有僱員薪酬均以市場水平釐定。除薪金以外，本集團亦提供僱員福利，包括醫療保險、員工強制性公積金供款及中國社會保險。為鼓勵及獎勵僱員，本集團制定酌情績效花紅及年終獎計劃，以推動僱員表現及成長。本公司亦設立購股權計劃及員工期權計劃以表揚僱員表現。

* For identification purpose only

* 僅供識別

ADDITIONAL INFORMATION

額外資料

1. DIRECTORS' AND CHIEF EXECUTIVE'S INTERESTS AND SHORT POSITIONS IN SHARES AND UNDERLYING SHARES

At 30 June 2022, the interests and short positions of the directors and chief executives of the Company and their associates in the shares and underlying shares of the Company and its associated corporations, as recorded in the register maintained by the Company pursuant to Section 352 of the Securities and Futures Ordinance (“SFO”), or as otherwise notified to the Company and The Stock Exchange of Hong Kong Limited (“the Stock Exchange”) pursuant to the Model Code for Securities Transactions by Directors of Listed Issuers (“Model Code”), were as follows:

LONG POSITIONS IN THE SHARES OF THE COMPANY

1. 董事及最高行政人員於股份及相關股份之權益及淡倉

於二零二二年六月三十日，本公司董事及最高行政人員以及彼等之聯繫人於本公司及其相聯法團之股份及相關股份中，擁有記錄於本公司根據證券及期貨條例（「證券及期貨條例」）第352條規定存置之登記冊，或根據上市發行人董事進行證券交易的標準守則（「標準守則」）已另行知會本公司及香港聯合交易所有限公司（「聯交所」）之權益及淡倉如下：

於本公司股份之好倉

Name of director	Capacity	Interest in shares	Interest in underlying shares	Total interest in shares	Approx. percentage of the issued share capital of the Company
董事姓名	身份	股份權益	相關股份權益	股份權益總額	佔本公司已發行股本概約百分比
Mr. Wang Zheng Chun 王正春先生	Beneficial owner 實益擁有人	5,468,750	30,000,000 (Note 3) (附註3)	35,468,750	0.58%
	Interest held by spouse 由配偶持有權益	35,074,000 (Note 1) (附註1)	-	35,074,000	0.58%
	Interest held by controlled corporation 由受控制法團持有之權益	64,811,000 (Note 2) (附註2)	-	64,811,000	1.07%
		105,353,750	30,000,000	135,353,750	2.23%

ADDITIONAL INFORMATION

額外資料

1. DIRECTORS' AND CHIEF EXECUTIVE'S INTERESTS AND SHORT POSITIONS IN SHARES AND UNDERLYING SHARES – continued

LONG POSITIONS IN THE SHARES OF THE COMPANY – continued

1. 董事及最高行政人員於股份及相關股份之權益及淡倉 – 續

於本公司股份之好倉 – 續

Name of director	Capacity	Interest in shares	Interest in underlying shares	Total interest in shares	Approx. percentage of the issued share capital of the Company
董事姓名	身份	股份權益	相關股份權益	股份權益總額	佔本公司已發行股本概約百分比
Mr. Zhu Shi Xing 祝仕興先生	Beneficial owner 實益擁有人	–	30,000,000 (Note 3) (附註3)	30,000,000	0.49%
Mr. Liu Xue Heng 劉學恒先生	Beneficial owner 實益擁有人	–	30,000,000 (Note 3) (附註3)	30,000,000	0.49%
Mr. Gu Shan Chao 顧善超先生	Beneficial owner 實益擁有人	–	30,000,000 (Note 3) (附註3)	30,000,000	0.49%
Mr. Siu Kin Wai 蕭健偉先生	Beneficial owner 實益擁有人	–	10,000,000 (Note 3) (附註3)	10,000,000	0.16%
Mr. Zhang Jing Ming 張景明先生	Beneficial owner 實益擁有人	–	20,000,000 (Note 3) (附註3)	20,000,000	0.33%
Mr. Hu Shiang Chi 胡湘麒先生	Beneficial owner 實益擁有人	–	15,000,000 (Note 3) (附註3)	15,000,000	0.25%
Mr. Robert Winslow Koepp 康仕學先生	Beneficial owner 實益擁有人	–	7,000,000 (Note 3) (附註3)	7,000,000	0.12%
Mr. Wu Yong Xin 吳永新先生	Beneficial owner 實益擁有人	–	4,000,000 (Note 3) (附註3)	4,000,000	0.07%
Mr. Tse Man Kit, Keith 謝文傑先生	Beneficial owner 實益擁有人	–	4,000,000 (Note 3) (附註3)	4,000,000	0.07%
Mr. Zhang Yun Zhou 張運周先生	Beneficial owner 實益擁有人	–	2,000,000 (Note 3) (附註3)	2,000,000	0.03%

1. DIRECTORS' AND CHIEF EXECUTIVE'S INTERESTS AND SHORT POSITIONS IN SHARES AND UNDERLYING SHARES – continued

LONG POSITIONS IN THE SHARES OF THE COMPANY – continued

Notes:

1. Mr. Wang Zheng Chun ("Mr. Wang") is deemed to be interested in 35,074,000 shares, being the interests beneficially held by his spouse, Madam Shen Ling Zhao.
2. The 64,811,000 shares are held by Hillfame Holdings Limited, a company incorporated in the British Virgin Islands and the entire issued share capital of which is beneficially owned by Mr. Wang.
3. The interests were derived from share options granted by the Company on 2 April 2015 and 28 January 2016 which entitled the holders thereof to subscribe for Shares at an exercise price of HK\$0.61 and HK\$0.53 per Share respectively. First 30% of the share options granted were vested from 2 April 2016 and 28 January 2017 (as the case may be), second 30% of the share options granted were vested from 2 April 2017 and 28 January 2018 (as the case may be) and remaining 40% of the share options granted were vested from 2 April 2018 and 28 January 2019 (as the case may be). The share options are exercisable from the vesting date until 1 April 2025 and 27 January 2026 (as the case may be).

Other than as disclosed above, none of the Directors and chief executives, nor their associates had any interests or short positions in any shares, underlying shares or debentures of the Company or any of its associated corporations as recorded in the register required to be kept under Section 352 of the SFO or as otherwise notified to the Company and the Stock Exchange pursuant to the Model Code.

1. 董事及最高行政人員於股份及相關股份之權益及淡倉 – 續

於本公司股份之好倉 – 續

附註：

1. 王正春先生(「王先生」)被視為於35,074,000股股份中擁有權益，而該等權益由彼之配偶沈領招女士實益持有。
2. 該64,811,000股股份由峰榮控股有限公司持有，該公司為於英屬處女群島註冊成立之公司，其全部已發行股本由王先生實益擁有。
3. 該等權益乃產生自本公司於二零一五年四月二日及二零一六年一月二十八日授出的購股權，該等購股權分別賦予其持有人權利以行使價每股股份0.61港元及每股股份0.53港元認購股份。已授出第一批30%購股權自二零一六年四月二日及二零一七年一月二十八日(視情況而定)起歸屬；已授出第二批30%購股權自二零一七年四月二日及二零一八年一月二十八日(視情況而定)起歸屬；及已授出餘下40%購股權自二零一八年四月二日及二零一九年一月二十八日(視情況而定)起歸屬。購股權可由歸屬日期起至二零二五年四月一日及二零二六年一月二十七日(視情況而定)行使。

除上文披露者外，概無董事及最高行政人員或彼等之聯繫人於本公司或其任何相聯法團之任何股份、相關股份或債權證中，擁有記錄於根據證券及期貨條例第352條規定須存置之登記冊，或根據標準守則已另行知會本公司及聯交所之任何權益或淡倉。

ADDITIONAL INFORMATION

額外資料

2. SUBSTANTIAL SHAREHOLDERS' INTERESTS AND SHORT POSITIONS IN SHARES AND UNDERLYING SHARES

Other than as disclosed above in the section headed "Directors' and chief executive's interests and short positions in shares and underlying shares", at 30 June 2022, the shareholders (other than the directors or chief executive of the Company) who had interests or short positions in the shares and underlying shares of the Company which would fall to be disclosed to the Company under the provisions of Divisions 2 and 3 of Part XV of the SFO or which were recorded in the register required to be kept by the Company under Section 336 of the SFO or had otherwise been notified to the Company were as follows:

LONG POSITIONS IN THE SHARES OF THE COMPANY

Name of shareholder 股東名稱/姓名	Capacity 身份	Number of shares beneficially held 實益擁有股份數目	Percentage of holding 持股百分比
Cosmic Stand International Limited	Beneficial owner 實益擁有人	945,000,000	15.55%
Beijing Enterprises Health and Medical Resources Group Limited 北控健康醫療資源集團有限公司	Interest held by controlled corporation (Note 1) 由受控制法團持有之權益(附註1)	945,000,000	15.55%
Beijing Properties (Holdings) Limited 北京建設(控股)有限公司	Interest held by controlled corporation (Note 1) 由受控制法團持有之權益(附註1)	945,000,000	15.55%
Brilliant Bright Holdings Limited 皓明控股有限公司	Interest held by controlled corporation (Note 1) 由受控制法團持有之權益(附註1)	945,000,000	15.55%
Beijing Enterprises Real Estate (HK) Limited 北控置業(香港)有限公司	Interest held by controlled corporation (Note 1) 由受控制法團持有之權益(附註1)	945,000,000	15.55%

2. 主要股東於股份及相關股份之權益及淡倉

除於上文「董事及最高行政人員於股份及相關股份之權益及淡倉」一節所披露者外，於二零二二年六月三十日，於本公司股份及相關股份中擁有根據證券及期貨條例第XV部第2及第3分部的條文須向本公司披露，或記錄於本公司須根據證券及期貨條例第336條規定置存的登記冊內，或已另行知會本公司的權益或淡倉之股東(本公司董事或最高行政人員除外)如下：

於本公司股份之好倉

ADDITIONAL INFORMATION

額外資料

2. SUBSTANTIAL SHAREHOLDERS' INTERESTS AND SHORT POSITIONS IN SHARES AND UNDERLYING SHARES – continued

2. 主要股東於股份及相關股份之權益及淡倉 – 續

LONG POSITIONS IN THE SHARES OF THE COMPANY – continued

於本公司股份之好倉 – 續

Name of shareholder 股東名稱/姓名	Capacity 身份	Number of shares beneficially held 實益擁有股份數目	Percentage of holding 持股百分比
Beijing Enterprises Real-Estate Group Limited 北京北控置業有限責任公司	Interest held by controlled corporation (Note 1) 由受控制法團持有之權益(附註1)	945,000,000	15.55%
Illumination Holdings Limited	Interest held by controlled corporation (Note 1) 由受控制法團持有之權益(附註1)	945,000,000	15.55%
Beijing Holdings Limited 京泰實業(集團)有限公司	Interest held by controlled corporation (Note 1) 由受控制法團持有之權益(附註1)	945,000,000	15.55%
Beijing Enterprises Group Company Limited 北京控股集團有限公司	Interest held by controlled corporation (Note 1) 由受控制法團持有之權益(附註1)	945,000,000	15.55%
Beijing Financial Holdings Group Limited 北京金融控股集團有限公司	Interest held by controlled corporation (Note 2) 由受控制法團持有之權益(附註2)	548,409,806	9.02%
Beijing Financial Investment Holdings Limited 北京金融投資控股有限公司	Interest held by controlled corporation (Note 2) 由受控制法團持有之權益(附註2)	548,409,806	9.02%
Beijing Investment Co., Limited 北京投資有限公司	Beneficial owner (Note 2) 實益擁有人(附註2)	548,409,806	9.02%
Ng Kin Nam 吳健南	Beneficial owner 實益擁有人	401,300,000	6.60%
Jangho Group Company Limited 江河創建集團股份有限公司	Interest held by controlled corporation (Note 3) 由受控制法團持有之權益(附註3)	324,684,000	5.34%

ADDITIONAL INFORMATION

額外資料

2. SUBSTANTIAL SHAREHOLDERS' INTERESTS AND SHORT POSITIONS IN SHARES AND UNDERLYING SHARES – continued

LONG POSITIONS IN THE SHARES OF THE COMPANY – continued

Notes:

1. These Shares were beneficially owned by Cosmic Stand International Limited. Cosmic Stand International Limited is wholly owned by Beijing Enterprises Health and Medical Resources Group Limited which is in turn wholly owned by Beijing Properties (Holdings) Limited. Beijing Properties (Holdings) Limited is owned as to 35.72%, 22.73%, 7.11% and 1.28% by Beijing Enterprises Real Estate (HK) Limited, Brilliant Bright Holdings Limited, Beijing Holdings Limited and Illumination Holdings Limited (a wholly-owned subsidiary of Beijing Enterprises Group Company Limited) respectively. Beijing Enterprises Real Estate (HK) Limited is wholly owned by Beijing Enterprises Real-Estate Group Limited which is in turn wholly owned by Beijing Enterprises Group Company Limited. Accordingly, these companies are deemed to be interested in the 945,000,000 Shares to beneficially owned by Cosmic Stand International Limited under the SFO.
2. These Shares were beneficially owned by Beijing Investment Co., Limited. Beijing Investment Co., Limited is wholly owned by Beijing Financial Holdings Group Limited which is in turn wholly owned by Beijing Financial Investment Holdings Limited. Accordingly, these companies are deemed to be interested in the 548,409,806 Shares beneficially owned by Beijing Investment Co., Limited under the SFO.

2. 主要股東於股份及相關股份之權益及淡倉－續

於本公司股份之好倉－續

附註：

1. 該等股份由 Cosmic Stand International Limited 實益擁有。Cosmic Stand International Limited 由北控健康醫療資源集團有限公司全資擁有，而北控健康醫療資源集團有限公司則由北京建設(控股)有限公司全資擁有。北京建設(控股)有限公司由北控置業(香港)有限公司、皓明控股有限公司、北京控股集團有限公司及 Illumination Holdings Limited (北京控股集團有限公司之全資附屬公司) 分別擁有 35.72%、22.73%、7.11% 及 1.28% 權益。北控置業(香港)有限公司由北京北控置業有限責任公司全資擁有，而北京北控置業有限責任公司則由北京控股集團有限公司全資擁有。因此，根據證券及期貨條例，此等公司被視為於 Cosmic Stand International Limited 實益擁有之 945,000,000 股股份中擁有權益。
2. 該等股份由北京投資有限公司實益擁有。北京投資有限公司由北京金融控股集團有限公司全資擁有，而北京金融控股集團有限公司則由北京金融投資控股有限公司全資擁有。因此，根據證券及期貨條例，該等公司被視為於北京投資有限公司實益擁有之 548,409,806 股股份中擁有權益。

2. SUBSTANTIAL SHAREHOLDERS' INTERESTS AND SHORT POSITIONS IN SHARES AND UNDERLYING SHARES – continued

LONG POSITIONS IN THE SHARES OF THE COMPANY – continued

Notes: – continued

3. 200,400,000 Shares were beneficially owned by Easy Glory Holding Limited, which is in turn wholly-owned by Gloryeild Enterprises Limited (“Gloryeild”). Gloryeild is wholly-owned by Sundart Holdings Limited and is indirectly wholly-owned by Jangho Curtain Wall Hong Kong Limited (“Jangho Curtain”). Jangho Curtain is wholly-owned by Jangho Group Company Limited (“Jangho”). 124,284,000 Shares were beneficially owned by Advance Finding Investments Limited, which is in turn wholly-owned by Peacemark Enterprises Limited (“Peacemark”). Peacemark is wholly-owned by Jangho Curtain and is indirectly wholly-owned by Jangho. Accordingly, Jangho is deemed to be interested in 324,684,000 Shares under the SFO.

Save as disclosed above and in the section headed “Directors’ and chief executive’s interests and short positions in shares and underlying shares”, at 30 June 2022, the Company had not been notified by any persons (other than the directors or chief executives of the Company) who had interests or short positions in the shares or underlying shares of the Company which would fall to be disclosed to the Company under the provisions of Divisions 2 and 3 of Part XV of the SFO, or which were recorded in the register required to be kept by the Company under Section 336 of the SFO.

2. 主要股東於股份及相關股份之權益及淡倉－續

於本公司股份之好倉－續

附註：－續

3. 200,400,000 股股份由 Easy Glory Holding Limited 實益擁有，而 Easy Glory Holding Limited 由 Gloryeild Enterprises Limited (「Gloryeild」) 全資擁有。Gloryeild 由承達集團有限公司全資擁有並由江河幕牆香港有限公司(「江河幕牆」)間接全資擁有。江河幕牆由江河創建集團股份有限公司(「江河」)全資擁有。124,284,000 股股份由 Advance Finding Investments Limited 實益擁有，而 Advance Finding Investments Limited 由 Peacemark Enterprises Limited (「Peacemark」) 全資擁有。Peacemark 由江河幕牆全資擁有並由江河間接全資擁有。因此，根據證券及期貨條例，江河被視為於 324,684,000 股股份中擁有權益。

除上文及「董事及最高行政人員於股份及相關股份之權益及淡倉」一節所披露者外，於二零二二年六月三十日，概無任何人士(本公司董事或最高行政人員除外)曾知會本公司擁有根據證券及期貨條例第XV部第2及第3分部之條文須向於本公司披露或記錄於根據證券及期貨條例第336條規定本公司須置存之登記冊內的本公司股份或相關股份之權益或淡倉。

ADDITIONAL INFORMATION

額外資料

3. SHARE OPTIONS

The details of the Company's share option scheme are set out in Note 15 of the interim condensed consolidated financial information. The following table discloses the number of outstanding share options of the Company at the beginning of the period and at 30 June 2022:

3. 購股權

本公司購股權計劃之詳情載於中期簡明綜合財務資料附註15內。下表披露期初及二零二二年六月三十日之本公司尚未行使購股權數目：

Category 類別	Number of share options at 1/1/2022 於二零二二年一月一日之購股權數目	Number of share options at 30/6/2022 於二零二二年六月三十日之購股權數目	Particulars at 30/6/2022 於二零二二年六月三十日之詳情	
			Share options granted on 2/4/2015 於二零一五年四月二日授出之購股權 (Note 1) (附註1)	Share options granted on 28/1/2016 於二零一六年一月二十八日授出之購股權 (Note 2) (附註2)
Mr. Wang Zheng Chun 王正春先生	30,000,000	30,000,000	20,000,000	10,000,000
Mr. Zhu Shi Xing 祝仕興先生	30,000,000	30,000,000	20,000,000	10,000,000
Mr. Liu Xue Heng 劉學恒先生	30,000,000	30,000,000	20,000,000	10,000,000
Mr. Gu Shan Chao 顧善超先生	30,000,000	30,000,000	20,000,000	10,000,000
Mr. Zhang Jing Ming 張景明先生	20,000,000	20,000,000	10,000,000	10,000,000
Mr. Siu Kin Wai 蕭健偉先生	10,000,000	10,000,000	10,000,000	-
Mr. Hu Shiang Chi 胡湘麒先生	15,000,000	15,000,000	5,000,000	10,000,000
Mr. Robert Winslow Koepf 康仕學先生	7,000,000	7,000,000	5,000,000	2,000,000
Mr. Wu Yong Xin 吳永新先生	4,000,000	4,000,000	2,000,000	2,000,000
Mr. Tse Man Kit, Keith 謝文傑先生	4,000,000	4,000,000	2,000,000	2,000,000
Mr. Zhang Yun Zhou 張運周先生	2,000,000	2,000,000	-	2,000,000
	182,000,000	182,000,000	114,000,000	68,000,000
Other employees and eligible persons 其他僱員及合資格人士	96,000,000	96,000,000	52,500,000	43,500,000
	278,000,000	278,000,000	166,500,000	111,500,000

3. SHARE OPTIONS – continued

Notes:

1. First 30% of the options granted were vested from 2 April 2016, second 30% of the options granted were vested from 2 April 2017 and the remaining 40% of the options granted were vested from 2 April 2018. Upon the lapse of the vesting period, the share options are exercisable until 1 April 2025.
2. First 30% of the options granted were vested from 28 January 2017, second 30% of the options granted were vested from 28 January 2018 and the remaining 40% of the options granted were vested from 28 January 2019. Upon the lapse of the vesting period, the share options are exercisable until 27 January 2026.

Save as disclosed above, at no time during the period was the Company, its holding company or any of its subsidiaries a party to any arrangement to enable the Directors to acquire benefits by means of the acquisition of shares in, or debentures of, the Company or any other body corporate.

3. 購股權 – 續

附註：

1. 首30%已授出購股權自二零一六年四月二日起歸屬，第二批30%已授出購股權自二零一七年四月二日起歸屬，而餘下40%已授出購股權自二零一八年四月二日起歸屬。於歸屬期失效後，購股權於二零二五年四月一日前均可予行使。
2. 首30%已授出購股權自二零一七年一月二十八日起歸屬，第二批30%已授出購股權自二零一八年一月二十八日起歸屬，而餘下40%已授出購股權自二零一九年一月二十八日起歸屬。於歸屬期失效後，購股權於二零二六年一月二十七日前均可予行使。

除上文披露者外，本公司、其控股公司或其任何附屬公司於期內任何時間概無訂立任何安排，致使董事可透過收購本公司或任何其他法人團體之股份或債權證而從中獲益。

ADDITIONAL INFORMATION

額外資料

4. PURCHASE, SALE OR REDEMPTION OF THE COMPANY'S LISTED SECURITIES

The Company had bought back its Shares on the Stock Exchange during the six months ended 30 June 2022 with details as follow:

4. 購買、出售或贖回本公司上市證券

本公司已於截至二零二二年六月三十日止六個月在聯交所購回股份，詳情如下：

Trading Day 交易日	Number of Shares Purchased 購回之股份數目	Price per Share 每股售價		Total Paid 支付總額 HK\$ 港元
		Highest Price Paid 支付之最高價格 HK\$ 港元	Lowest Price Paid 支付之最低價格 HK\$ 港元	
1 June 2022 二零二二年六月一日	5,190,000	0.093	0.089	474,108
2 June 2022 二零二二年六月二日	6,522,000	0.095	0.092	612,786
6 June 2022 二零二二年六月六日	4,200,000	0.097	0.093	403,200
7 June 2022 二零二二年六月七日	1,728,000	0.100	0.097	172,656
8 June 2022 二零二二年六月八日	1,476,000	0.104	0.100	149,094
14 June 2022 二零二二年六月十四日	1,056,000	0.105	0.096	107,766
	<u>20,172,000</u>			<u>1,919,610</u>

All of the shares bought back during the six months ended 30 June 2022 were cancelled on 22 July 2022.

Save as disclosed, there was no purchase, sale or redemption by the Company or any of its subsidiaries, of the Company's listed securities during the six months ended 30 June 2022.

於截至二零二二年六月三十日止六個月購回之所有股份於二零二二年七月二十二日註銷。

除所披露者外，於截至二零二二年六月三十日止六個月，本公司或其任何附屬公司並無購買、出售或贖回本公司的上市證券。

ADDITIONAL INFORMATION

額外資料

5. COMPLIANCE WITH THE MODEL CODE OF THE LISTING RULES

The Board has adopted the provisions of the Model Code for Securities Transactions by Directors of Listed Issuers (the “Model Code”) as set out in Appendix 10 to the Listing Rules. The Company confirms that, after specific enquiry with each director, each of the directors has confirmed compliance with the Model Code for the six months ended 30 June 2022.

6. CORPORATE GOVERNANCE CODE

The Company has complied with the code provisions of the Corporate Governance Code (the “CG Code”) as set out in Appendix 14 of the Listing Rules for the six months ended 30 June 2022.

7. AUDIT COMMITTEE

The Audit Committee was established on 11 April 2002 with written terms of reference. The Board establishes formal and transparent arrangements for considering how it applies the financial reporting and internal control principles and for maintaining an appropriate relationship with the Company’s auditors.

The Audit Committee currently comprises three independent non-executive directors, namely Mr. Tse Man Kit, Keith (Chairman), Mr. Wu Yong Xin, and Mr. Gary Zhao.

The Company’s interim results announcement for the six months ended 30 June 2022 have been reviewed by the Audit Committee of the Company, and the interim report for the six months ended 30 June 2022 are not audited but have been reviewed by the Audit Committee of the Company.

5. 遵守上市規則之標準守則

董事會已採納上市規則附錄十所載之上市發行人董事進行證券交易的標準守則(「標準守則」)之條文。本公司經向各董事作出特定查詢後確認，全體董事確認於截至二零二二年六月三十日止六個月均有遵守標準守則。

6. 企業管治守則

本公司於截至二零二二年六月三十日止六個月內一直遵守上市規則附錄14所載企業管治守則(「企業管治守則」)之守則條文。

7. 審核委員會

審核委員會於二零零二年四月十一日成立，並以書面訂明職權範圍。董事會就考慮財務報告及內部監控原則之應用，以及與本公司核數師維持適當關係方面，作出正式及具透明度之安排。

審核委員會成員現時包括三名獨立非執行董事謝文傑先生(主席)、吳永新先生及趙剛先生。

本公司審核委員會已審閱本公司截至二零二二年六月三十日止六個月之中期業績公告，而截至二零二二年六月三十日止六個月之中期報告未經審核，但已由本公司審核委員會審閱。

ADDITIONAL INFORMATION

額外資料

8. REMUNERATION COMMITTEE

The Remuneration Committee was established on 23 May 2006 with written terms of reference. The main objective of the remuneration policy is to ensure that the Group is able to attract, retain and motivate a high calibre team which is essential to the success of the Group.

The members of the Remuneration Committee currently include three independent non-executive directors, Mr. Gary Zhao (chairman), Mr. Tse Man Kit, Keith and Mr. Wu Yong Xin.

9. NOMINATION COMMITTEE

The Nomination Committee was established on 23 May 2006 with written terms of reference. It establishes the formal process for identifying and nominating the suitable candidates for the appointment of the Board, reviews the structure, size and composition of the Board and makes recommendations to the Board with regard to any adjustments that are deemed necessary.

The members of the Nomination Committee currently include three independent non-executive directors, Mr. Wu Yong Xin (chairman), Mr. Tse Man Kit, Keith, Mr. Gary Zhao and one executive director, Mr. Zhu Shi Xing.

8. 薪酬委員會

薪酬委員會於二零零六年五月二十三日成立，並以書面訂明其職權範圍。薪酬政策的主要目的為確保本集團可吸引、挽留及激勵對本集團成功非常關鍵的具才幹隊伍。

薪酬委員會成員現時包括三名獨立非執行董事趙剛先生(主席)、謝文傑先生及吳永新先生。

9. 提名委員會

提名委員會於二零零六年五月二十三日成立，並以書面訂明其職權範圍。提名委員會就物色及提名合適人選出任董事制訂正式程序、檢討董事會結構、規模及組成，並就其認為必要作出的任何調整，向董事會提供推薦意見。

提名委員會成員現時包括三名獨立非執行董事吳永新先生(主席)、謝文傑先生及趙剛先生，以及一名執行董事祝仕興先生。

10. INVESTMENT AND RISK MANAGEMENT COMMITTEE

On 8 October 2014, the Company established the Investment and Risk Management Committee with written terms of reference. The principal duties of the Investment and Risk Management Committee include overseeing the risk management and evaluating the major investment and funding projects of the Group.

The Investment and Risk Management Committee comprises four members, namely, Mr. Gu Shan Chao (chairman), Mr. Zhu Shi Xing, Mr. Liu Xue Heng and Mr. Lam Ka Tak.

11. CHANGES IN DIRECTORS' BIOGRAPHICAL DETAILS UNDER RULE 13.51B(1) OF LISTING RULES

In accordance with Rule 13.51B(1) of the Listing Rules, the change in the information of the directors of the Company since the date of 2021 Annual Report of the Company is set out below:

- Mr. Hu Shiang Chi, an executive Director of the Company, resigned as a director of Dr. Chip Biotech, Inc. (stock code in Taiwan GreTai Securities Market: 4131) on 2 August 2022.

10. 投資及風險管理委員會

於二零一四年十月八日，本公司成立投資及風險管理委員會，並以書面訂明其職權範圍。投資及風險管理委員會之主要職務包括監管風險管理，並評估本集團主要投資及資金項目。

投資及風險管理委員會由四名成員組成，包括顧善超先生（主席）、祝仕興先生、劉學恒先生及林嘉德先生。

11. 根據上市規則第13.51B(1)條披露董事之履歷詳情變動

根據上市規則第13.51B(1)條，自本公司之二零二一年年報日期起，本公司董事之資料變動列載如下：

- 胡湘麒先生，本公司執行董事，於二零二二年八月二日，辭任晶宇生物科技實業股份有限公司（台灣證券櫃檯買賣中心股份代號：4131）之董事職務。

CORPORATE INFORMATION

公司資料

BOARD OF DIRECTORS

EXECUTIVE DIRECTORS

Mr. Zhu Shi Xing (*Chairman*)
Mr. Liu Xue Heng (*Chief Executive Officer*)
(Re-designated on 15 July 2022)
Mr. Zhang Jing Ming (*Joint Chief Executive Officer*)
(Resigned on 15 July 2022)
Mr. Siu Kin Wai
Mr. Gu Shan Chao
Mr. Hu Shiang Chi
Mr. Wang Zheng Chun

INDEPENDENT NON-EXECUTIVE DIRECTORS

Mr. Gary Zhao
Mr. Robert Winslow Koepf
Mr. Tse Man Kit, Keith
Mr. Wu Yong Xin
Mr. Zhang Yun Zhou

AUTHORISED REPRESENTATIVES

Mr. Lam Ka Tak
Mr. Liu Xue Heng

COMPANY SECRETARY

Mr. Lam Ka Tak

AUDIT COMMITTEE

Mr. Tse Man Kit, Keith (*Chairman of the committee*)
Mr. Gary Zhao
Mr. Wu Yong Xin

REMUNERATION COMMITTEE

Mr. Gary Zhao (*Chairman of the committee*)
Mr. Tse Man Kit, Keith
Mr. Wu Yong Xin

NOMINATION COMMITTEE

Mr. Wu Yong Xin (*Chairman of the committee*)
Mr. Gary Zhao
Mr. Tse Man Kit, Keith
Mr. Zhu Shi Xing

INVESTMENT AND RISK MANAGEMENT COMMITTEE

Mr. Gu Shan Chao (*Chairman of the committee*)
Mr. Liu Xue Heng
Mr. Zhu Shi Xing
Mr. Lam Ka Tak

董事會

執行董事
祝仕興先生(主席)
劉學恒先生(行政總裁)
(於二零二二年七月十五日調任)
張景明先生(聯席行政總裁)
(於二零二二年七月十五日辭任)
蕭健偉先生
顧善超先生
胡湘麒先生
王正春先生

獨立非執行董事

趙剛先生
康仕學先生
謝文傑先生
吳永新先生
張運周先生

法定代表

林嘉德先生
劉學恒先生

公司秘書

林嘉德先生

審核委員會

謝文傑先生(委員會主席)
趙剛先生
吳永新先生

薪酬委員會

趙剛先生(委員會主席)
謝文傑先生
吳永新先生

提名委員會

吳永新先生(委員會主席)
趙剛先生
謝文傑先生
祝仕興先生

投資及風險管理委員會

顧善超先生(委員會主席)
劉學恒先生
祝仕興先生
林嘉德先生

CORPORATE INFORMATION

公司資料

AUDITORS

Ernst & Young
Certified Public Accountants

LEGAL ADVISER

Sidney Austin
DLA Piper Hong Kong

STOCK CODE

2389

WEBSITE

www.bjhl.com.hk

PRINCIPAL BANKERS

Bank of Beijing
China Citic Bank International
Shanghai Pudong Development Bank
Bank of Jinzhou

REGISTERED OFFICE

Cricket Square
Hutchins Drive
P.O. Box 2681, KY1-1111
Grand Cayman
Cayman Islands

HEAD OFFICE AND PRINCIPAL PLACE OF BUSINESS

Unit 2704, 27/F
909 Cheung Sha Wan Road
Cheung Sha Wan, Kowloon
Hong Kong

PRINCIPAL SHARE REGISTRAR AND TRANSFER OFFICE

Suntera (Cayman) Limited
Suite 3204, Unit 2A, Block 3
Building D, P.O. Box 1586
Gardenia Court, Camana Bay
Grand Cayman, KY1-1110
Cayman Islands

HONG KONG BRANCH SHARE REGISTRAR AND TRANSFER OFFICE

Union Registrars Limited
Suites 3301-04, 33/F
Two Chinachem Exchange Square
338 King's Road
North Point
Hong Kong

核數師

安永會計師事務所
執業會計師

法律顧問

盛德律師事務所
歐華律師事務所

股份代號

2389

網址

www.bjhl.com.hk

主要往來銀行

北京銀行
中信銀行(國際)
上海浦東發展銀行
錦州銀行

註冊辦事處

Cricket Square
Hutchins Drive
P.O. Box 2681, KY1-1111
Grand Cayman
Cayman Islands

總辦事處及主要營業地點

香港
九龍長沙灣
長沙灣道909號
27樓2704室

股份過戶登記總處

Suntera (Cayman) Limited
Suite 3204, Unit 2A, Block 3
Building D, P.O. Box 1586
Gardenia Court, Camana Bay
Grand Cayman, KY1-1110
Cayman Islands

香港股份過戶登記分處

聯合證券登記有限公司
香港
北角
英皇道338號
華懋交易廣場2期
33樓3301-04室



北京健康(控股)有限公司
Beijing Health (Holdings) Limited